UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ | QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, |
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ |
Commission File Number: 001-38546
NEURONETICS, INC.
(Exact name of registrant as specified in its charter)
| |
Delaware | 33-1051425 |
(State or other jurisdiction of | (I.R.S. Employer Identification No.) |
incorporation or organization) | |
| |
3222 Phoenixville Pike, Malvern, PA | 19355 |
(Address of principal executive offices) | (Zip Code) |
(610) 640-4202 | |
(Registrant’s telephone number, including area code) | |
Not applicable.
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class |
| Trading |
| Name on each exchange on which registered |
Common Stock ($0.01 par value) | | STIM | | The Nasdaq Global Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | |
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
There were 27,221,49028,933,132 shares of the registrant’s common stock outstanding as of November 4, 2022.2, 2023.
NEURONETICS, INC.
Quarterly Report on Form 10-Q for the quarterly period ended September 30, 20222023
Table of Contents
2
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
NEURONETICS, INC.
Balance Sheets
(Unaudited; In thousands, except per share data)
| | | | | | |
| | September 30, | | December 31, | ||
|
| 2022 |
| 2021 | ||
Assets |
| |
|
| |
|
Current assets: |
| |
|
| |
|
Cash and cash equivalents | | $ | 73,698 | | $ | 94,141 |
Accounts receivable, net | |
| 11,963 | |
| 7,706 |
Inventory | |
| 8,573 | |
| 6,563 |
Current portion of net investments in sales-type leases | |
| 1,874 | |
| 2,198 |
Current portion of prepaid commission expense | |
| 1,871 | |
| 1,559 |
Current portion of note receivables | | | 80 | | | 74 |
Prepaid expenses and other current assets | |
| 3,037 | |
| 3,090 |
Total current assets | |
| 101,096 | |
| 115,331 |
Property and equipment, net | |
| 2,109 | |
| 1,220 |
Operating lease right-of-use assets | |
| 3,459 | |
| 3,884 |
Net investments in sales-type leases | |
| 1,617 | |
| 1,697 |
Prepaid commission expense | |
| 7,305 | |
| 6,763 |
Long-term note receivable | | | 94 | |
| 10,110 |
Other assets | |
| 3,555 | |
| 2,218 |
Total Assets | | $ | 119,235 | | $ | 141,223 |
Liabilities and Stockholders’ Equity | |
|
| |
| |
Current liabilities: | |
|
| |
| |
Accounts payable | | $ | 2,350 | | $ | 4,299 |
Accrued expenses | |
| 11,493 | |
| 8,233 |
Deferred revenue | |
| 1,732 | |
| 2,501 |
Current portion of operating lease liabilities | |
| 818 | |
| 670 |
Current portion of long-term debt, net | |
| 8,750 | |
| — |
Total current liabilities | |
| 25,143 | |
| 15,703 |
Long-term debt, net | |
| 27,009 | |
| 35,335 |
Deferred revenue | |
| 981 | |
| 1,471 |
Operating lease liabilities | |
| 3,111 | |
| 3,539 |
Total Liabilities | |
| 56,244 | |
| 56,048 |
Commitments and contingencies (Note 17) | |
| — | |
| — |
Stockholders’ Equity: | |
|
| |
| |
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or | |
|
| |
| |
outstanding on September 30, 2022, and December 31, 2021 | |
| — | |
| — |
Common stock, $0.01 par value: 200,000 shares authorized; 27,060 and 26,395 | |
|
| |
| |
shares issued and outstanding on September 30, 2022, and December 31, 2021, respectively | |
| 270 | |
| 264 |
Additional paid-in capital | |
| 400,323 | |
| 393,644 |
Accumulated deficit | |
| (337,602) | |
| (308,733) |
Total Stockholders' Equity | |
| 62,991 | |
| 85,175 |
Total Liabilities and Stockholders’ Equity | | $ | 119,235 | | $ | 141,223 |
| | | | | | | |
| | September 30, | | December 31, | | ||
|
| 2023 |
| 2022 | | ||
Assets |
| |
|
| |
| |
Current assets: |
| |
|
| |
| |
Cash and cash equivalents | | $ | 35,847 | | $ | 70,340 | |
Accounts receivable, net | |
| 15,024 | |
| 13,591 | |
Inventory | |
| 9,737 | |
| 8,899 | |
Current portion of net investments in sales-type leases | |
| 968 | |
| 1,538 | |
Current portion of prepaid commission expense | |
| 2,351 | |
| 1,997 | |
Current portion of notes receivable | | | 1,850 | | | 230 | |
Prepaid expenses and other current assets | |
| 5,234 | |
| 2,174 | |
Total current assets | |
| 71,011 | |
| 98,769 | |
Property and equipment, net | |
| 2,066 | |
| 1,991 | |
Operating lease right-of-use assets | |
| 2,916 | |
| 3,327 | |
Net investments in sales-type leases | |
| 700 | |
| 1,222 | |
Prepaid commission expense | |
| 8,018 | |
| 7,568 | |
Long-term notes receivable | | | 4,191 | |
| 362 | |
Other assets | |
| 4,086 | |
| 3,645 | |
Total Assets | | $ | 92,988 | | $ | 116,884 | |
Liabilities and Stockholders’ Equity | |
|
| |
| | |
Current liabilities: | |
|
| |
| | |
Accounts payable | | $ | 2,822 | | $ | 2,433 | |
Accrued expenses | |
| 10,037 | |
| 14,837 | |
Deferred revenue | |
| 1,637 | |
| 1,980 | |
Current portion of operating lease liabilities | |
| 840 | |
| 824 | |
Current portion of long-term debt, net | |
| — | |
| 13,125 | |
Total current liabilities | |
| 15,336 | |
| 33,199 | |
Long-term debt, net | |
| 36,851 | |
| 22,829 | |
Deferred revenue | |
| 354 | |
| 829 | |
Operating lease liabilities | |
| 2,506 | |
| 2,967 | |
Total Liabilities | |
| 55,047 | |
| 59,824 | |
Commitments and contingencies (Note 17) | |
| — | |
| — | |
Stockholders’ Equity: | |
|
| |
| | |
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on September 30, 2023, and December 31, 2022 | |
| — | |
| — | |
Common stock, $0.01 par value: 200,000 shares authorized; 28,902 and 27,268 shares issued and outstanding on September 30, 2023, and December 31, 2022, respectively | |
| 289 | |
| 273 | |
Additional paid-in capital | |
| 408,356 | |
| 402,679 | |
Accumulated deficit | |
| (370,704) | |
| (345,892) | |
Total Stockholders' Equity | |
| 37,941 | |
| 57,060 | |
Total Liabilities and Stockholders’ Equity | | $ | 92,988 | | $ | 116,884 | |
The accompanying notes are an integral part of these unaudited interim financial statements.
3
NEURONETICS, INC.
Statements of Operations
(Unaudited; In thousands, except per share data)
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended | | Three Months Ended | | Nine Months Ended | | ||||||||||||||||
| | September 30, | | September 30, | | September 30, | | September 30, | | ||||||||||||||||
| | 2022 | | 2021 | | 2022 | | 2021 | | 2023 | | 2022 | | 2023 | | 2022 | | ||||||||
Revenues |
| $ | 16,498 |
| $ | 13,799 | | $ | 47,008 |
| $ | 40,290 |
| $ | 17,884 |
| $ | 16,498 | | $ | 51,034 |
| $ | 47,008 | |
Cost of revenues | |
| 3,570 | |
| 3,144 | |
| 11,093 | |
| 8,115 | |
| 6,120 | |
| 3,570 | |
| 15,100 | |
| 11,093 | |
Gross Profit | |
| 12,928 | |
| 10,655 | |
| 35,915 | |
| 32,175 | |
| 11,764 | |
| 12,928 | |
| 35,934 | |
| 35,915 | |
Operating expenses: | |
| | |
|
| |
|
| |
|
| |
| | |
|
| |
|
| |
|
| |
Sales and marketing | |
| 11,643 | |
| 9,827 | |
| 37,977 | |
| 27,431 | |
| 12,141 | |
| 11,643 | |
| 35,602 | |
| 37,977 | |
General and administrative | |
| 6,391 | |
| 6,435 | |
| 19,125 | |
| 19,220 | |
| 6,339 | |
| 6,391 | |
| 19,151 | |
| 19,125 | |
Research and development | |
| 2,348 | |
| 1,575 | |
| 6,197 | |
| 6,179 | |
| 2,155 | |
| 2,348 | |
| 7,308 | |
| 6,197 | |
Total operating expenses | |
| 20,382 | |
| 17,837 | |
| 63,299 | |
| 52,830 | |
| 20,635 | |
| 20,382 | |
| 62,061 | |
| 63,299 | |
Loss from Operations | |
| (7,454) | |
| (7,182) | |
| (27,384) | |
| (20,655) | |||||||||||||
Loss from operations | |
| (8,871) | |
| (7,454) | |
| (26,127) | |
| (27,384) | | ||||||||||||
Other (income) expense: | |
| | |
|
| |
|
| |
|
| |
| | |
|
| |
|
| |
|
| |
Interest expense | |
| 1,061 | |
| 993 | |
| 3,039 | |
| 2,955 | |
| 1,184 | |
| 1,061 | |
| 3,580 | |
| 3,039 | |
Other income, net | |
| (906) | |
| (24) | |
| (1,554) | |
| (53) | |
| (664) | |
| (906) | |
| (4,895) | |
| (1,554) | |
Net Loss | | $ | (7,609) | | $ | (8,151) | | $ | (28,869) | | $ | (23,557) | | $ | (9,391) | | $ | (7,609) | | $ | (24,812) | | $ | (28,869) | |
Net loss per share of common stock outstanding, basic and diluted | | $ | (0.28) | | $ | (0.31) | | $ | (1.08) | | $ | (0.94) | | $ | (0.33) | | $ | (0.28) | | $ | (0.87) | | $ | (1.08) | |
Weighted-average common shares outstanding, basic and diluted | |
| 26,965 | |
| 26,301 | |
| 26,797 | |
| 25,179 | |
| 28,876 | |
| 26,965 | |
| 28,505 | |
| 26,797 | |
| | | | | | | | | | | | | |
The accompanying notes are an integral part of these unaudited interim financial statements.
4
NEURONETICS, INC.
Statements of Changes in Stockholders’ Equity
(Unaudited; In thousands)
| | | | | | | | | | | | | | |
|
|
|
| |
| Additional |
|
|
| Total | ||||
| | Common Stock | | Paid-in | | Accumulated | | Stockholders’ | ||||||
|
| Shares |
| Amount |
| Capital |
| Deficit |
| Equity | ||||
Balance at December 31, 2020 |
| 19,114 | | $ | 191 | | $ | 302,842 | | $ | (277,540) | | $ | 25,493 |
Share-based awards and options exercises |
| 1,076 | |
| 11 | |
| 1,581 | |
| — | |
| 1,592 |
Issuance of common stock, net of issuance costs of $401 | | 5,566 | | | 56 | | | 80,515 | | | — | | | 80,571 |
Share-based compensation expense |
| — | |
| — | |
| 2,196 | |
| — | |
| 2,196 |
Net loss |
| — | |
| — | |
| — | |
| (7,881) | |
| (7,881) |
Balance at March 31, 2021 |
| 25,756 | | $ | 258 | | $ | 387,134 | | $ | (285,421) | | $ | 101,971 |
Share-based awards and options exercises |
| 411 | |
| 4 | |
| 707 | |
| — | |
| 711 |
Share-based compensation expense |
| — | |
| — | |
| 2,009 | |
| — | |
| 2,009 |
Net loss |
| — | |
| — | |
| — | |
| (7,525) | |
| (7,525) |
Balance at June 30, 2021 |
| 26,167 | | $ | 262 | | $ | 389,850 | | $ | (292,946) | | $ | 97,166 |
Share-based awards and options exercises |
| 168 | |
| 1 | |
| 99 | |
| — | |
| 100 |
Share-based compensation expense |
| — | |
| — | |
| 1,961 | |
| — | |
| 1,961 |
Net loss |
| — | |
| — | |
| — | |
| (8,151) | |
| (8,151) |
Balance at September 30, 2021 |
| 26,335 | | $ | 263 | | $ | 391,910 | | $ | (301,097) | | $ | 91,076 |
| | | | | | | | | | | | | | |
Balance at December 31, 2021 |
| 26,395 | | $ | 264 | | $ | 393,644 | | $ | (308,733) | | $ | 85,175 |
Share-based awards and options exercises |
| 322 | |
| 3 | |
| 6 | |
| — | |
| 9 |
Share-based compensation expense |
| — | |
| — | |
| 2,252 | |
| — | |
| 2,252 |
Net loss |
| — | |
| — | |
| — | |
| (10,838) | |
| (10,838) |
Balance at March 31, 2022 |
| 26,717 | | $ | 267 | | $ | 395,902 | | $ | (319,571) | | $ | 76,598 |
Share-based awards and options exercises |
| 139 | |
| 1 | |
| 42 | |
| — | |
| 43 |
Share-based compensation expense |
| — | |
| — | |
| 2,203 | |
| — | |
| 2,203 |
Net loss |
| — | |
| — | |
| — | |
| (10,422) | |
| (10,422) |
Balance at June 30, 2022 |
| 26,856 | | $ | 268 | | $ | 398,147 | | $ | (329,993) | | $ | 68,422 |
Share-based awards and options exercises |
| 204 | |
| 2 | |
| (2) | |
| — | |
| — |
Share-based compensation expense |
| — | |
| — | |
| 2,178 | |
| — | |
| 2,178 |
Net loss |
| — | |
| — | |
| — | |
| (7,609) | |
| (7,609) |
Balance at September 30, 2022 |
| 27,060 | | $ | 270 | | $ | 400,323 | | $ | (337,602) | | $ | 62,991 |
| | | | | | | | | | | | | | |
|
|
|
| |
| Additional |
|
|
| Total | ||||
| | Common Stock | | Paid-in | | Accumulated | | Stockholders’ | ||||||
|
| Shares |
| Amount |
| Capital |
| Deficit |
| Equity | ||||
Balance at December 31, 2021 |
| 26,395 | | $ | 264 | | $ | 393,644 | | $ | (308,733) | | $ | 85,175 |
Share-based awards and options exercises |
| 322 | |
| 3 | |
| 6 | |
| — | |
| 9 |
Share-based compensation expense |
| — | |
| — | |
| 2,252 | |
| — | |
| 2,252 |
Net loss |
| — | |
| — | |
| — | |
| (10,838) | |
| (10,838) |
Balance at March 31, 2022 |
| 26,717 | | $ | 267 | | $ | 395,902 | | $ | (319,571) | | $ | 76,598 |
Share-based awards and options exercises |
| 139 | |
| 1 | |
| 42 | |
| — | |
| 43 |
Share-based compensation expense |
| — | |
| — | |
| 2,203 | |
| — | |
| 2,203 |
Net loss |
| — | |
| — | |
| — | | | (10,422) | |
| (10,422) |
Balance at June 30, 2022 |
| 26,856 | | $ | 268 | | $ | 398,147 | | $ | (329,993) | | $ | 68,422 |
Share-based awards and options exercises |
| 204 | |
| 2 | |
| (2) | |
| — | |
| — |
Share-based compensation expense |
| — | |
| — | |
| 2,178 | |
| — | |
| 2,178 |
Net loss |
| — | |
| — | |
| — | |
| (7,609) | |
| (7,609) |
Balance at September 30, 2022 |
| 27,060 | | $ | 270 | | $ | 400,323 | | $ | (337,602) | | $ | 62,991 |
| | | | | | | | | | | | | | |
Balance at December 31, 2022 |
| 27,268 | | $ | 273 | | $ | 402,679 | | $ | (345,892) | | $ | 57,060 |
Share-based awards and options exercises |
| 1,197 | |
| 12 | |
| (12) | |
| — | |
| — |
Share-based compensation expense |
| — | |
| — | |
| 1,805 | |
| — | |
| 1,805 |
Net loss |
| — | |
| — | |
| — | |
| (10,520) | |
| (10,520) |
Balance at March 31, 2023 |
| 28,465 | | $ | 285 | | $ | 404,472 | | $ | (356,412) | | $ | 48,345 |
Share-based awards and options exercises |
| 348 | |
| 3 | |
| (3) | |
| — | |
| — |
Share-based compensation expense |
| — | |
| — | |
| 2,033 | |
| — | |
| 2,033 |
Net loss |
| — | |
| — | |
| — | |
| (4,901) | |
| (4,901) |
Balance at June 30, 2023 |
| 28,813 | | $ | 288 | | $ | 406,502 | | $ | (361,313) | | $ | 45,477 |
Share-based awards and options exercises |
| 89 | |
| 1 | |
| (1) | |
| — | |
| — |
Share-based compensation expense |
| — | |
| — | |
| 1,855 | |
| — | |
| 1,855 |
Net loss |
| — | |
| — | |
| — | |
| (9,391) | |
| (9,391) |
Balance at September 30, 2023 |
| 28,902 | | $ | 289 | | $ | 408,356 | | $ | (370,704) | | $ | 37,941 |
The accompanying notes are an integral part of these unaudited interim financial statements.
5
NEURONETICS, INC.
Statements of Cash Flows
(Unaudited; In thousands)
| | | | | | | |
| | Nine Months Ended September 30, | | ||||
| | 2022 | | 2021 | | ||
Cash Flows from Operating Activities: |
| |
|
| |
| |
Net loss | | $ | (28,869) | | $ | (23,557) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |
|
| |
|
| |
Depreciation and amortization | |
| 1,044 | |
| 768 | |
Share-based compensation | |
| 6,633 | |
| 6,166 | |
Non-cash interest expense | |
| 513 | |
| 484 | |
Cost of rental units purchased by customers | |
| 92 | |
| 137 | |
Changes in certain assets and liabilities: | |
| | |
|
| |
Accounts receivable, net | |
| (4,257) | |
| (3,097) | |
Inventory | |
| (2,299) | |
| (1,870) | |
Net investments in sales-type leases | |
| 381 | |
| 341 | |
Prepaid commission expense | |
| (854) | |
| (602) | |
Prepaid expenses and other assets | |
| 176 | |
| (453) | |
Accounts payable | |
| (2,199) | |
| (840) | |
Accrued expenses | |
| 3,260 | |
| (405) | |
Deferred revenue | |
| (1,260) | |
| (531) | |
Net Cash Used in Operating Activities | |
| (27,639) | |
| (23,459) | |
| | | | | | | |
Cash Flows from Investing Activities: | |
|
| |
|
| |
Purchases of property and equipment and capitalized software | |
| (2,766) | |
| (1,552) | |
Repayment (Issuance) of promissory note | | | 10,000 | | | (7,486) | |
Net Cash provided by (used in) Investing Activities | |
| 7,234 | |
| (9,038) | |
| |
| | | | | |
Cash Flows from Financing Activities: | |
|
| |
|
| |
Payments of debt issuance costs | |
| (90) | |
| — | |
Proceeds from exercises of stock options | |
| 52 | |
| 2,403 | |
Proceeds from the issuance of common stock | |
| — | |
| 80,972 | |
Payments of common stock offering issuance costs | |
| — | |
| (401) | |
Net Cash (used in) Provided by Financing Activities | |
| (38) | |
| 82,974 | |
Net (Decrease) Increase in Cash and Cash Equivalents | |
| (20,443) | |
| 50,477 | |
Cash and Cash Equivalents, Beginning of Period | |
| 94,141 | |
| 48,957 | |
Cash and Cash Equivalents, End of Period | | $ | 73,698 | | $ | 99,434 | |
Supplemental disclosure of cash flow information: | |
|
| |
|
| |
Cash paid for interest | | $ | 2,525 | | $ | 2,471 | |
Transfer of Inventory to PP&E | | | 285 | | | 235 | |
Supplemental disclosure of non-cash investing and financing activities: | |
|
| |
|
| |
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | | $ | 251 | | $ | 398 | |
Reduction of accounts receivable in long-term note receivable | | | — | | | 2,514 | |
| | | | | | | |
| | | | | | | |
| | Nine Months Ended September 30, | | ||||
| | 2023 | | 2022 | | ||
Cash Flows from Operating Activities: |
| |
|
| |
| |
Net loss | | $ | (24,812) | | $ | (28,869) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |
|
| |
|
| |
Depreciation and amortization | |
| 1,503 | |
| 1,044 | |
Allowance for credit losses | | | 369 | | | 328 | |
Inventory impairment | | | 1,905 | | | — | |
Share-based compensation | |
| 5,693 | |
| 6,633 | |
Non-cash interest expense | |
| 460 | |
| 513 | |
Cost of rental units purchased by customers | |
| — | |
| 92 | |
Changes in certain assets and liabilities: | |
| | |
|
| |
Accounts receivable, net | |
| (7,933) | |
| (4,585) | |
Inventory | |
| (2,742) | |
| (2,299) | |
Net investments in sales-type leases | |
| 1,092 | |
| 381 | |
Prepaid commission expense | |
| (804) | |
| (854) | |
Prepaid expenses and other assets | |
| (3,338) | |
| 176 | |
Accounts payable | |
| 54 | |
| (2,199) | |
Accrued expenses | |
| (4,801) | |
| 3,260 | |
Deferred revenue | |
| (817) | |
| (1,260) | |
Net Cash Used in Operating Activities | |
| (34,171) | |
| (27,639) | |
| | | | | | | |
Cash Flows from Investing Activities: | |
|
| |
|
| |
Purchases of property and equipment and capitalized software | |
| (1,490) | |
| (2,766) | |
Repayment of notes receivable | | | 731 | | | 10,000 | |
Net Cash (Used in) Provided by Investing Activities | |
| (759) | |
| 7,234 | |
| |
| | | | | |
Cash Flows from Financing Activities: | |
|
| |
|
| |
Payments of debt issuance costs | |
| (863) | |
| (90) | |
Proceeds from issuance of long-term debt | | | 2,500 | | | — | |
Repayment of long-term debt | | | (1,200) | | | — | |
Proceeds from exercises of stock options | |
| — | |
| 52 | |
Net Cash Provided by (Used in) Financing Activities | |
| 437 | |
| (38) | |
Net Decrease in Cash and Cash Equivalents | |
| (34,493) | |
| (20,443) | |
Cash and Cash Equivalents, Beginning of Period | |
| 70,340 | |
| 94,141 | |
Cash and Cash Equivalents, End of Period | | $ | 35,847 | | $ | 73,698 | |
Supplemental disclosure of cash flow information: | |
|
| |
|
| |
Cash paid for interest | | $ | 3,120 | | $ | 2,525 | |
Transfer of inventory to property and equipment | | | — | | | 285 | |
Supplemental disclosure of non-cash investing and financing activities: | |
|
| |
|
| |
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | | $ | 335 | | $ | 251 | |
Reduction of accounts receivable in current and long-term notes receivable | | | 6,330 | | | — | |
| | | | | | | |
The accompanying notes are an integral part of these unaudited interim financial statements.
6
1. DESCRIPTION OF BUSINESS
Neuronetics, Inc., or the Company, (the “Company”) is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation or TMS,(“TMS”) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States (“U.S.”) Food and Drug Administration or the FDA,(the “FDA”) to treat adult patients with major depressive disorder or MDD,(“MDD”) who have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode. OurThe NeuroStar Advanced Therapy system was also cleared in 2022 by the FDA to treat people suffering from obsessive-compulsive disorder as well as for the treatment of comorbid anxiety symptoms for adults with MDD suffering from anxiety symptoms (“anxious depression”). NeuroStar Advanced TherapySystem is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of itsthe NeuroStar Advanced Therapy System for additional indications.
COVID-19
The Company is continuing to monitor the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will continue to impact the Company’s customers, supply chain, employees and other business partners. While the Company experienced significant disruptions in March 2020 through the end of September 30, 2022 from the COVID-19 pandemic, it is unable to predict the full impact that the pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the ongoing pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic, vaccination rates, effectiveness of treatments, and containment measures, among others. The pandemic has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets, and may contribute to periods of economic uncertainty in the future.
Liquidity
As of September 30, 2022,2023, the Company had cash and cash equivalents of $73.7$35.8 million and an accumulated deficit of $337.6$370.7 million. The Company incurred negative cash flows from operating activities of $27.6$34.2 million for the nine months ended September 30, 20222023 and $28.0$30.7 million for the year ended December 31, 2021.2022. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its initial public offering (“IPO”) of common stock,, private placements of its convertible preferred securities, borrowings under its credit facility, proceeds from its secondary public offering of common stock and revenues from sales of its products. As of September 30, 2022,2023, the Company had $35.0$37.5 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025March 2028. Subsequent to September 30, 2023, the Company drew down an additional $22.5 million pursuant to the terms of its amended credit facility. Management believes that the Company’s cash and cash equivalents as of September 30, 2022,2023, and anticipated revenues from sales of its products are sufficient to fund the Company’s operations for at least the next 12 months from the issuance of these financial statements.
2. BASIS OF PRESENTATION
The accompanying financial statements have been prepared in accordance with United StatesU.S. generally accepted accounting principles or GAAP.(“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification or ASC,(“ASC”) and Accounting Standards Updates or ASUs,(“ASUs”) promulgated by the Financial Accounting Standards Board or FASB.(“FASB”).
7
Interim Financial Statements
The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United StatesU.S. Securities and Exchange Commission or SEC,(the “SEC”), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ equity and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes that the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and nine months ended September 30, 20222023 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 8, 2022,7, 2023, wherein a more complete discussion of significant accounting policies and certain other information can be found.
7
Use of Estimates
The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes that its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, including those related to the COVID-19 pandemic, and given the subjective element of the estimates and assumptions, made, actual results may differ materially from estimated results.
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company’s complete summary of significant accounting policies can be found in “Note 3. Summary of Significant Accounting Policies” in the audited financial statements included in the Company’s Form 10-K filed with the SEC on March 8, 2022.7, 2023.
4. RECENT ACCOUNTING PRONOUNCEMENTS
New Accounting Standards Not Yet Adopted by the Company
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”). This ASU provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The FASB subsequently issued ASU 2019-04, to clarify and address certain items related to the amendments in Topic 326.
ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief, was issued to provide entities that have certain instruments within the scope of ASC 326 with an option to irrevocably elect the fair value option under ASC 825-10, Financial Instruments - Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU 2019-10, Topic 326, Topic 815, and Topic 842 amendsamend the mandatory effective date for Topic 326.
8
These ASUs are effective for fiscal years beginning after December 15, 2022 for entities that are eligible to be defined by the SEC as a smaller reporting company. The Company isadopted Topic 326 with an adoption date of January 1, 2023 using the modified retrospective approach. As a smaller reporting company. Althoughresult, the impact uponCompany changed its accounting policy for allowance for credit losses. The Company monitors accounts receivable and long-term notes receivable and estimates the allowance for lifetime expected credit losses. Estimates of expected credit losses are based on historical collection experience and other factors, including those related to current market conditions and events. The adoption will dependdid not have a material effect on the Company's financial instruments held by the Company at that time, the Company does not anticipate a significant impact on its financial statements based on the instruments currently held and its historical trend of bad debt expense relating to trade accounts receivable.statements.
Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our unaudited interim financial statements.
8
5. FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS
The carrying values of cash equivalents, accounts receivable, prepaids and other current assets, and accounts payable on the Company’s balance sheets approximated their fair values as of September 30, 20222023 and December 31, 20212022 due to their short-term nature. The carrying values of the Company’s credit facility approximated its fair value as of September 30, 20222023 and December 31, 20212022 due to its variable interest rate. The carrying value of the Company’s notenotes receivable approximated its fair value as of September 30, 2023 and December 31, 20212022 due to its variable interest rate.
Certain of the Company’s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
Level 1: | Inputs are quoted prices for identical instruments in active markets. |
Level 2: | Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. |
Level 3: | Inputs are unobservable and reflect the Company’s own assumptions, based on the best information available, including the Company’s own data. |
The following tables set forth the carrying amounts and fair values of the Company’s financial instruments as of September 30, 20222023 and December 31, 20212022 (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| September 30, 2022 |
| September 30, 2023 | ||||||||||||||||||||||||||
| | | | | | | | Fair Value Measurement Based on | | | | | | | | Fair Value Measurement Based on | ||||||||||||||
| | | | | | | | Quoted | | Significant | | | | | | | | | | | Quoted | | Significant | | | | ||||
| | | | | | | | Prices In | | other | | Significant | | | | | | | | Prices In | | other | | Significant | ||||||
| | | | | | | | Active | | Observable | | Unobservable | | | | | | | | Active | | Observable | | Unobservable | ||||||
| | Carrying | | | | | Markets | | Inputs | | Inputs | | Carrying | | | | | Markets | | Inputs | | Inputs | ||||||||
|
| Amount |
| Fair Value |
| (Level 1) |
| (Level 2) |
| (Level 3) |
| Amount |
| Fair Value |
| (Level 1) |
| (Level 2) |
| (Level 3) | ||||||||||
Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Money market funds (cash equivalents) | | $ | 69,405 | | $ | 69,405 | | $ | 69,405 | | $ | — | | $ | — | | $ | 27,163 | | $ | 27,163 | | $ | 27,163 | | $ | — | | $ | — |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| December 31, 2021 |
| December 31, 2022 | ||||||||||||||||||||||||||
| | | | | | | | Fair Value Measurement Based on | | | | | | | | Fair Value Measurement Based on | ||||||||||||||
| | | | | | | | Quoted | | Significant | | | | | | | | | | | Quoted | | Significant | | | | ||||
| | | | | | | | Prices In | | other | | Significant | | | | | | | | Prices In | | other | | Significant | ||||||
| | | | | | | | Active | | Observable | | Unobservable | | | | | | | | Active | | Observable | | Unobservable | ||||||
| | Carrying | | | | | Markets | | Inputs | | Inputs | | Carrying | | | | | Markets | | Inputs | | Inputs | ||||||||
| | Amount | | Fair Value | | (Level 1) | | (Level 2) | | (Level 3) | | Amount | | Fair Value | | (Level 1) | | (Level 2) | | (Level 3) | ||||||||||
Assets |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
Money market funds (cash equivalents) | | $ | 91,236 | | $ | 91,236 | | $ | 91,236 | | $ | — | | $ | — | | $ | 68,002 | | $ | 68,002 | | $ | 68,002 | | $ | — | | $ | — |
9
6. ACCOUNTS RECEIVABLE
The following table presents the composition of accounts receivable, net as of September 30, 20222023 and December 31, 20212022 (in thousands):
| | | | | | | | | | | | | |
| | September 30, | | December 31, | | September 30, | | December 31, | | ||||
|
| 2022 |
| 2021 |
| 2023 |
| 2022 | | ||||
Gross accounts receivable - trade | | $ | 13,754 | | $ | 9,168 | | $ | 16,155 | | $ | 15,239 | |
Less: Allowances for doubtful accounts | |
| (1,791) | |
| (1,462) | |||||||
Less: Allowances for credit losses | |
| (1,131) | |
| (1,648) | | ||||||
Accounts receivable, net | | $ | 11,963 | | $ | 7,706 | | $ | 15,024 | | $ | 13,591 | |
7. INVENTORY
Inventory is stated at the lower of cost and net realizable value, with cost being determined on a first in, first out basis. The Company’s inventory is primarily comprised of finished goods. During the three months ended September 30, 2023, the Company recorded a $1.9 million inventory impairment for specialized component parts secured for discontinued NeuroStar Advanced Therapy Systems whose cost exceeds net realizable value.
7.8. PROPERTY AND EQUIPMENT AND CAPITALIZED SOFTWARE
The following table presents the composition of property and equipment, net as of September 30, 20222023 and December 31, 20212022 (in thousands):
| | | | | | | | | | | | | | |
| | September 30, | | December 31, | | | September 30, | | December 31, | | ||||
|
| 2022 |
| 2021 | |
| 2023 |
| 2022 | | ||||
Laboratory equipment | | $ | 466 | | $ | 249 | | | $ | 666 | | $ | 462 | |
Office equipment | |
| 508 | |
| 497 | | |
| 510 | |
| 508 | |
Computer equipment and software | |
| 1,711 | |
| 1,598 | | |
| 1,966 | |
| 1,758 | |
Manufacturing equipment | |
| 344 | |
| 341 | | |
| 485 | |
| 343 | |
Leasehold improvements | |
| 1,422 | |
| 471 | | |
| 1,442 | |
| 1,435 | |
Rental equipment | |
| 575 | |
| 601 | | |
| 542 | |
| 542 | |
Property and equipment, gross | |
| 5,026 | |
| 3,757 | | |
| 5,611 | |
| 5,048 | |
Less: Accumulated depreciation | |
| (2,917) | |
| (2,537) | | |
| (3,545) | |
| (3,057) | |
Property and equipment, net | | $ | 2,109 | | $ | 1,220 | | | $ | 2,066 | | $ | 1,991 | |
As of September 30, 20222023 and December 31, 2021,2022, the Company had capitalized software costs, net of $3.7$3.9 million and $2.5$3.6 million, respectively, which are included in “Prepaid expenses and other current assets” and “Other assets” on the balance sheet.
Depreciation and amortization expense was $0.4$0.5 million and $0.2$0.4 million for the three months ended September 30, 20222023 and 2021,2022, respectively, and $1.0$1.5 million and $0.8$1.0 million for the nine months ended September 30, 20222023 and 2021,2022, respectively.
10
9. NOTES RECEIVABLE
Greenbrook TMS Inc.
On March 31, 2023, the Company entered into a Secured Promissory Note and Guaranty Agreement (the “Promissory Note”) with TMS Neurohealth Centers Inc. (the “Maker”) and Greenbrook TMS Inc. and its subsidiaries, excluding the Maker (the “Guarantors”), in the principal amount of $6.0 million for a period of four years.
The Promissory Note will bear interest at a rate equal to the sum of (a) the floating interest rate of daily secured overnight financing rate as administered by the Federal Reserve Bank of New York on its website (“SOFR”) plus (b) 7.65%.
Pursuant to the terms of the Promissory Note, in the event of an event of default thereunder, the Maker will be required to issue common share purchase warrants to the Company equal to (i) 200% of the unpaid amount of any delinquent amount or payment due and payable under the Promissory Note, together with all outstanding and unpaid accrued interest, fees, charges and costs, divided by (ii) the exercise price of the warrants, which will represent a 20% discount to the 30-day volume-weighted average closing price of Greenbrook TMS Inc.’s common shares traded on the Nasdaq Stock Market (“Nasdaq”) prior to the date of issuance (subject to any limitations that may be required by Nasdaq).
Under the Promissory Note and related loan documents, the Maker and the Guarantors have granted to the Company a security interest in substantially all of the Maker’s and the Guarantors’ assets and the Guarantors have guaranteed the Maker’s obligations under the Promissory Note. The Company’s security interest pursuant to the Promissory Note and related loan documents ranks pari passu with the Maker’s senior lender, Madryn Fund Administration, LLC, and is subject to an intercreditor agreement.
Success TMS
On September 29, 2021, Neuronetics, Inc. the Company entered into an exclusive, five-year master sales agreement (the “Commercial Agreement”) with Check Five LLC d/b/adoing business as Success TMS (“Success TMS”). In connection with the Commercial Agreement, the Company agreed to loan Success TMS the principal amount of $10.0 million for a period of five years pursuant to a secured promissory note (the “Note”). The Note bore interest at a floating rate equal to the prime rate plus 6.00% per annum. The Note included an interest-only period through October 1, 2022, after which time Success TMS was required to make monthly payments of principal and interest. Under the terms of the Note, the Company had received a first priority security interest in substantially all of the assets of Success TMS. Success TMS has also granted the Company an observer seat on the Board of Managers of Success TMS.
10
In the Note, Success TMS made certain representations and warranties and was required to comply with certain customary affirmative and negative covenants during the term of the Note.
On April 29, 2022, the Company entered into a Subordination Agreement (the “Subordination Agreement”) with ZW Partners, LLC, a New Jersey limited liability company (“ZW Partners”), pursuant to which the Company agreed to subordinate its rights under the Note to the rights of ZW Partners under a revolving promissory note, dated as of April 29, 2022 (the “Senior Note”), issued by Success TMS to ZW Partners in an amount up to $10.0 million. As a result, payments in respect of the Note were subordinate and subject in right and time of payment to payment in full of the Senior Note, and ZW Partners’ liens and security interests upon the collateral securing both the Senior Note and the Note are superior in priority to the Company’s liens and security interests upon such collateral. Under the Agreement, the Company had the right to purchase, at par, the entire aggregate amount of debt under the Senior Note at any time.
On July 14, 2022, Success TMS repaid in full the Note issued on September 29, 2021 with a cash payment of $10.5 million, which included all outstanding principal, prepayment premium and accrued but unpaid interest. The repayment extinguished the Note in its entirety and terminated the Subordination Agreement entered into by the Company and ZW Partners.Company.
Interest income recognized by the Company related to notes receivable was $0.2 million and $0.5 million for the three months ended September 30, 2023 and 2022, respectively.
Interest income recognized by the Company related to notes receivable was $0.4 million and $1.0 million for the three and nine months ended September 30, 2023 and 2022, respectively.
| | | | | | |
| | September 30, | | December 31, | ||
|
| 2023 |
| 2022 | ||
Current portion of notes receivable | | $ | 1,890 | | $ | 230 |
Long-term notes receivable | |
| 4,299 | |
| 362 |
Less: Allowances for credit losses | | | (148) | | | — |
Notes receivable, net | | $ | 6,041 | | $ | 592 |
11
9.10. LEASES
Lessee:
The Company has operating leases for its corporate headquarters, a training facility and office equipment, including copiers. The Company leases an approximately 32,000 square foot facility in Malvern, Pennsylvania for its corporate headquarters, which includes office and warehouse space. The Company leases an approximately 9,600 square foot facility in Charlotte, North Carolina as a training facility for its NeuroStar Advanced Therapy Systems. The Company does not currently have any finance leases or executed leases that have not yet commenced.
Operating lease rent expense was $0.2 million and $0.2 million for the three months ended September 30, 2023 and 2022, and 2021, respectively, and $0.6 million and $0.4 million for the nine months ended September 30, 20222023 and 2021, respectively.2022. As of September 30, 2022,2023, the weighted-average remaining lease term of operating leases was 5.34.3 years and the weighted-average discount rate was 7.1%7.2%.
The following table presents the supplemental cash flow information as a lessee related to leases (in thousands):
| | | | | | | | | | | | | | |
|
| Nine Months Ended | |
| Nine Months Ended | | ||||||||
| | September 30, 2022 |
| September 30, 2021 | | | September 30, 2023 |
| September 30, 2022 | | ||||
Cash paid for amounts included in the measurement of lease liabilities: |
| |
|
| |
| |
| |
|
| |
| |
Operating cash flows from operating leases | | $ | 632 | | $ | 526 | | | $ | 807 | | $ | 632 | |
11
The following table sets forth by year the required future payments of operating lease liabilities (in thousands):
| | | | | | | |
| | September 30, 2022 | | September 30, 2023 | | ||
Remainder of 2022 | | $ | 209 | ||||
2023 | | | 852 | ||||
Remainder of 2023 | | $ | 215 | | |||
2024 | |
| 875 | | | 875 | |
2025 | |
| 898 | |
| 898 | |
2026 | |
| 921 | |
| 921 | |
Thereafter | |
| 999 | ||||
2027 | |
| 882 | | |||
2028 | |
| 116 | | |||
Total lease payments | |
| 4,754 | |
| 3,907 | |
Less imputed interest | |
| (825) | |
| (561) | |
Present value of operating lease liabilities | | $ | 3,929 | | $ | 3,346 | |
Lessor sales-type leases:
Certain customers have purchased NeuroStar Advanced Therapy Systems on a rent-to-own basis. The lease term is three or four years with a customer option to purchase the NeuroStar Advanced Therapy System at the end of the lease or automatic transfer of ownership of the NeuroStar Advanced Therapy System at the end of the lease.
The following table sets forth the profit recognized on sales-type leases (in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, | | Nine Months Ended September 30, | | Three Months Ended September 30, | | Nine Months Ended September 30, | | ||||||||||||||||
|
| 2022 |
| 2021 |
| 2022 |
| 2021 |
| 2023 |
| 2022 |
| 2023 |
| 2022 | | ||||||||
Profit recognized at commencement, net | | $ | 122 | | $ | 262 | | $ | 543 | | $ | 543 | | $ | 13 | | $ | 122 | | $ | 60 | | $ | 543 | |
Interest income | |
| — | |
| — | |
| — | |
| — | |
| — | |
| — | |
| — | |
| — | |
Total sales-type lease income | | $ | 122 | | $ | 262 | | $ | 543 | | $ | 543 | | $ | 13 | | $ | 122 | | $ | 60 | | $ | 543 | |
12
The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands):
| | | | | | |
|
| September 30, |
| September 30, | ||
| | 2022 | | 2023 | ||
Remainder of 2022 | | $ | 605 | |||
2023 | | | 1,572 | |||
Remainder of 2023 | | $ | 298 | |||
2024 | |
| 858 | | | 876 |
2025 | |
| 368 | |
| 390 |
2026 | | | 88 | |
| 76 |
2027 | | | 28 | |||
Total sales-type lease receivables | | $ | 3,491 | | $ | 1,668 |
As of September 30, 2022,2023, the carrying amount of the lease receivables is $3.5$1.7 million. The Company does not have any unguaranteed residual assets.
Lessor operating leases:
NeuroStar Advanced Therapy Systems sold for which collection is not probable are accounted for as operating leases. For the three months ended September 30, 20222023 and 2021,2022, the Company recognized operating lease income of $0.07$0.02 million and $0.03$0.07 million, respectively. For the nine months ended September 30, 20222023 and 2021,2022, the Company recognized operating lease income of $0.2$0.1 million and $0.2 million, respectively.
12
The Company maintained Rental Equipment,rental equipment, net of $0.5$0.4 million and $0.6$0.5 million as of September 30, 20222023 and December 31, 2021,2022, respectively, which are included in “Property and equipment, net” on the balance sheet. Rental equipment depreciation expense was $0.02 million and $0.01 million for the three months ended September 30, 2023 and 2022, and 2021, respectively, and $0.07 million and $0.03 million for the nine months ended September 30, 2023 and 2022, and 2021.respectively.
10.11. PREPAID COMMISSION EXPENSE
The Company pays a commission on both NeuroStar Advanced Therapy System sales and Treatment Sessiontreatment session sales. Since the commission paid for Systemsystem sales is not commensurate with the commission paid for Treatment Sessions,treatment sessions, the Company capitalizes commission expense associated with NeuroStar Advanced Therapy System sales commissions paid that is incremental to specifically anticipated future Treatment Sessiontreatment session orders. In developing this estimate, the Company considered its historical Treatment Sessiontreatment session sales and customer retention rates, as well as technology development life cycles and other industry factors. These costs are periodically reviewed for impairment.
NeuroStar Advanced Therapy System commissions are deferred and amortized on a straight-line basis over a seven-year period equal to the average customer term, which the Company deems to be the expected period of benefit for these costs.
On the Company’s balance sheets, the current portion of capitalized contract costs is represented by the current portion of prepaid commission expense, while the long-term portion is included in prepaid commission expense. Amortization expense was $0.5$0.6 million and $0.3$0.5 million for the three months ended September 30, 20222023 and 2021,2022, respectively, and $1.3$1.7 million and $0.9$1.3 million for the nine months ended September 30, 20222023 and 2021,2022, respectively.
13
11.12. ACCRUED EXPENSES
The following table presents the composition of accrued expenses as of September 30, 20222023 and December 31, 20212022 (in thousands):
| | | | | | | | | | | | |
|
| September 30, |
| December 31, |
| September 30, |
| December 31, | ||||
| | 2022 | | 2021 | | 2023 | | 2022 | ||||
Compensation and related benefits | | $ | 8,022 | | $ | 5,090 | | $ | 6,342 | | $ | 11,201 |
Consulting and professional fees | |
| 760 | |
| 537 | |
| 713 | |
| 761 |
Research and development expenses | |
| 637 | |
| 388 | |
| 278 | |
| 678 |
Sales and marketing expenses | | | 246 | | | 268 | | | 1,012 | | | 410 |
Warranty | |
| 337 | |
| 306 | |
| 198 | |
| 328 |
Sales and other taxes payable | |
| 558 | |
| 664 | |
| 641 | |
| 659 |
Other | |
| 933 | |
| 980 | |
| 853 | |
| 800 |
Accrued expenses | | $ | 11,493 | | $ | 8,233 | | $ | 10,037 | | $ | 14,837 |
12.13. DEFERRED REVENUE
Payment terms typically require payment upon shipment or installation of the NeuroStar Advanced Therapy System and additional payments as access codes for Treatment Sessionstreatment sessions are delivered, which can span several years after the Systemsystem is first delivered and installed. The timing of revenue recognition compared to billings and cash collections typically results in accounts receivable. However, sometimes customer advances and deposits mightmay be required for certain customers and are recorded as contract liabilities (deferred revenue). For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual coverage period and recognizes revenue over the term of the coverage period.
13
As of September 30, 2022,2023, the Company expects to recognize approximately the following percentages of deferred revenue by year:
| | | | | | |
|
| Revenue |
|
| Revenue |
|
Year: | | Recognition |
| | Recognition |
|
Remainder of 2022 | | 25 | % | |||
2023 |
| 40 | % | |||
Remainder of 2023 | | 29 | % | |||
2024 |
| 25 | % |
| 59 | % |
2025 |
| 8 | % |
| 11 | % |
2026 | | 2 | % |
| 1 | % |
Total |
| 100 | % |
| 100 | % |
Revenue recognized for the three and nine months ended September 30, 2023 and 2022 that was included in the contract liability balance at the beginning of the year was $0.4 million. Revenue recognized for the nine months ended September 30, 2023 and 2022 that was included in the contract liability balance at the beginning of the year was $1.7 million and $2.2 million, respectively, and primarily represented revenue earned from separately priced extended warranties, customer deposits, milestone revenue, and clinical training.
Customers
Significant customers are those that represent more than 10% of the Company’s total revenue. For the three months ended September 30, 20222023 and 2021,2022, one customer accounted for more than 10%15% and 15% of the Company’s revenues,revenue, respectively. For the nine months ended September 30, 20222023 and 2021,2022, one customer accounted for more than 10%17% and 16% of the Company’s revenues,revenue, respectively.
13. DEBT
The following table presentsAccounts receivable outstanding related to the composition of debtcustomer was $2.1 million and $5.2 million as of September 30, 20222023 and December 31, 2021 (in thousands):
| | | | | | | |
| | September 30, | | December 31, | | ||
|
| 2022 |
| 2021 | | ||
Outstanding principal | | $ | 35,000 | | $ | 35,000 | |
Accrued final payment fees | |
| 1,925 | |
| 1,925 | |
Less debt discounts | |
| (1,166) | |
| (1,590) | |
Total debt, net | |
| 35,759 | |
| 35,335 | |
Less current portion | |
| (8,750) | |
| — | |
Long-term debt, net | | $ | 27,009 | | $ | 35,335 | |
For the three months ended September 30, 2022, the Company recognized interest expense of $1.1 million, of which $0.9 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the three months ended September 30, 2021, the Company recognized interest expense of $1.0 million, of which $0.8 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.
For the nine months ended September 30, 2022, the Company recognized interest expense of $3.0 million, of which $2.5 million was cash and $0.5 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.
Solar Credit Facility
On March 2, 2020, the Company entered into a loan and security agreement with Solar Capital Ltd., or Solar, as collateral agent, and other lenders defined in the agreement, for a credit facility, or the Solar Facility, thatrespectively.
14
replaced the Company’s previous $35.0 million credit facility with Oxford Finance LLC, or Oxford, and such facility, the Oxford Facility.
The Solar Facility originally permitted the Company to borrow up to an aggregate amount of $50.0 million in two tranches of term loans, a “Term A Loan” and “Term B Loan.” On March 2, 2020, the Company borrowed an aggregate amount of $35.0 million, which was the aggregate amount available under the Term A Loan portion of the Solar Facility. The Term A Loan portion of the Solar Facility matures, and all amounts borrowed thereunder are due, on February 28, 2025. Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of $15.0 million, (i) upon the Company achieving a specified amount of trailing twelvemonths net product revenue, and (ii)assuming there has been no event of default under the Solar Facility prior to such election. Once the net product revenue condition has been satisfied, the Company may make an election to borrow under the Term B Loan portion of the Solar Facility until the earlier of (a)December15, 2021, (b)30days following achievement of the net product revenue condition or (c)the occurrence of an event of default.
Each of the Term A Loan and Term B Loan accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. The Term A Loan and the Term B Loan both include an interest-only period through March 1, 2022, after which time the Company will be required to make monthly payments of principal and interest. Monthly principal payments are to be paid in equal amounts on a pro rata basis to lenders. At the Company’s election, the interest only period may be extended through February 2023 if the Company satisfies a minimum net product revenue covenant through March 1, 2022 and no event of default shall have occurred.
In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar due upon the earlier of prepayment, acceleration or the maturity date of the Term A Loan or Term B Loan portion of the Solar Facility equal to 5.50% of the principal amount of the term loans actually funded. The Company is accruing the final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing. If the Company prepays either of the Term A Loan or Term B Loan prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of funding, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of funding, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of funding of the principal amounts borrowed.
The Company is also required to pay Solar an exit fee upon the occurrence, prior to March 2, 2030, of (a) any liquidation, dissolution or winding up of the Company, (b) transaction that results in a person obtaining control over the Company, (c) the Company achieving $100 million in trailing twelve month net product revenue or (d) the Company achieving $125 million in trailing twelve month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 4.50% of the principal amount of the term loans actually funded. The exit fee for achieving either $100 million or $125 million in trailing twelve-month net product revenue is equal to 2.25% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 4.50% of the principal amount of the term loans actually funded. The exit fee is capped at 4.50% of the principal amount of the term loans actually funded.
15
The Company’s obligations under the Solar Facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The loan and security agreement requires the Company to comply with certain financial covenants, including the attainment of a minimum trailing net revenue amount beginning on December 31, 2020, as well as customary affirmative and negative covenants.
The Solar Facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) material cross-defaults; (vii) significant judgments, orders or decrees for payments by the Company not covered by insurance; (viii) incorrectness of representations and warranties; (ix) incurrence of subordinated debt; (x) a termination or breach of a guaranty; (xi) revocation of governmental approvals necessary for the Company to conduct its business; and (xii) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. The Solar Facility includes subjective acceleration clauses which permit the lenders to accelerate the maturity date under certain circumstances, including, but not limited to, material adverse effects on a Company’s financial status or otherwise.
On December 8, 2020, the Company, Solar Capital Ltd., and our other lenders defined in the Solar Facility, executed an amendment to the Solar Facility (the “Solar Amendment”). The Solar Amendment divided the aggregate Term B Loan borrowing amount of $15.0 million allowable upon our achievement of specific trailing twelve-month net product revenue targets into three separate $5.0 million tranches (“Amended Term B Loan”, “Term C Loan” and “Term D Loan”). The three tranches are available through June 20, 2021, December 20, 2021, and June 20, 2022, respectively, based on the achievement of agreed upon trailing twelve-month net product revenue targets for each tranche.
The Solar Amendment also reduced the trailing twelve-month net product revenue requirement for the Amended Term B Loan portion of the facility. Subject to certain conditions, the Company has the ability to extend the interest only period on the initial Term A Loan to 36 months from 24 months upon achieving the revenue targets associated with the Amended Term B Loan. The Company was required to pay an amendment fee of $0.1 million to Solar, which was recognized as a deferred debt issuance cost as of December 31, 2020 that will be amortized to interest expense using the effective interest method.
On February 15, 2022, the Company, SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), and our other lenders defined in the Solar Facility, executed an amendment to the Solar Facility and the Solar Amendment (the “2022 Solar Amendment”). The 2022 Solar Amendment waived any default under the Solar Facility and Solar Amendment that resulted from the Company’s failure to comply with the minimum monthly trailing twelve months net product revenue financial covenant, beginning with the testing period for the calendar month ending December 31, 2021 and continuing to the execution date of the 2022 Solar Amendment; (ii) decreased the amount of trailing twelve months net product revenue that the Company is required to achieve, for testing periods on and from the calendar month ending January 31, 2022; (iii) modified the definition of the fourth draw period with respect to the Company’s ability to borrow the Term D Loan portion of the Solar Facility, such that after giving effect to the 2022 Solar Amendment, the Term D Loan portion of the Solar Facility is no longer available to be drawn by the Company; and (iv) modified the definition of interest only extension conditions to allow commencement of loan principal amortization under the Solar Facility to be extended to March 1, 2023. The Company was required to pay an amendment fee of $0.06 million to Solar, which has been recognized as a deferred debt issuance cost as of March 31, 2022 that will be amortized to interest expense using the effective interest method.
As of September 30, 2022, the Company is in compliance with all covenants in the Solar Facility and is projected to be in compliance with the reduced minimum revenue covenant amounts going forward.
16
14. COMMON STOCK
Common Stock Offering
On February 2, 2021, we closed on our public offering and sale (the “Offering”) of our common stock in which we issued and sold 5,566,000 shares of our common stock, which included shares pursuant to an option granted to underwriters to purchase additional shares, at a public offering price of $15.50 per share. We received net proceeds of $80.6 million after deducting underwriting discounts, commissions and offering expenses.
Common Stock
The following table summarizes the total number of shares of the Company’s common stock issued and reserved for issuance as of September 30, 2022 and December 31, 2021 (in thousands):
| | | | |
|
| September 30, 2022 |
| December 31, 2021 |
Shares of common stock issued |
| 27,060 |
| 26,395 |
Shares of common stock reserved for issuance for: |
|
|
|
|
Common stock warrants outstanding |
| 75 |
| 75 |
Stock options outstanding |
| 1,424 |
| 1,499 |
Restricted stock units outstanding |
| 4,060 |
| 2,124 |
Shares available for grant under stock incentive plan |
| 1,067 |
| 2,037 |
Shares available for sale under employee stock purchase plan |
| 1,063 |
| 799 |
Total shares of common stock issued and reserved for issuance |
| 34,749 |
| 32,929 |
Common Stock Warrants
The following tables summarize the Company’s outstanding common stock warrants as of September 30, 2022, and December 31, 2021:
| | | | | |
September 30, 2022 |
|
| |
|
|
Warrants |
|
| |
|
|
Outstanding | | | | | |
(in thousands) | | Exercise Price | | Expiration Date | |
14 | | $ | 19.55 |
| Dec-2022 |
20 | | $ | 9.73 |
| Aug-2023 |
20 | | $ | 9.73 |
| Mar-2024 |
21 | | $ | 9.73 |
| Dec-2024 |
75 | |
|
|
|
|
| | | | | |
December 31, 2021 |
|
| |
|
|
Warrants |
|
| |
|
|
Outstanding | | | | | |
(in thousands) | | Exercise Price | | Expiration Date | |
14 | | $ | 19.55 |
| Dec-2022 |
20 | | $ | 9.73 |
| Aug-2023 |
20 | | $ | 9.73 |
| Mar-2024 |
21 | | $ | 9.73 |
| Dec-2024 |
75 | |
|
|
|
|
15. LOSS PER SHARE
The Company’s basic loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. The Company’s restricted stock awards
17
(non-vested shares) are issued and outstanding at the time of grant but are excluded from the Company’s computation of weighted-average shares outstanding in the determination of basic loss per share until vesting occurs.
A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options, non-vested restricted stock units and non-vested performance restricted stock units using the treasury stock method, along with the effect, if any, from the potential conversion of outstanding securities, such as convertible preferred stock.
The following potentially dilutive securities outstanding as of September 30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):
| | | | | |
| | September 30, | | ||
|
| 2022 |
| 2021 | |
Stock options | | 1,424 | | 1,567 | |
Non-vested performance restricted stock units |
| 395 |
| 395 | |
Non-vested restricted stock units |
| 3,665 |
| 1,647 | |
Common stock warrants |
| 75 |
| 75 | |
16. SHARE-BASED COMPENSATION
The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):
| | | | | | | | | | | | | |
|
| Three Months Ended September 30, | | Nine Months Ended September 30, | | ||||||||
| | 2022 |
| 2021 |
| 2022 |
| 2021 | | ||||
Cost of revenues | | $ | 35 | | $ | 23 | | $ | 94 | | | 56 | |
Sales and marketing | |
| 1,074 | |
| 515 | |
| 3,258 | | | 1,608 | |
General and administrative | |
| 939 | |
| 1,368 | |
| 2,950 | | | 4,368 | |
Research and development | |
| 130 | |
| 55 | |
| 331 | | | 134 | |
Total | | $ | 2,178 | | $ | 1,961 | | $ | 6,633 | | $ | 6,166 | |
2018 Equity Incentive Plan
In June 2018, the Company adopted the 2018 Equity Incentive Plan, or 2018 Plan, which authorized the issuance of up to 1.4 million shares, subject to an annual 4% increase based on the number of shares of common stock outstanding, in the form of restricted stock, stock appreciation rights and stock options to the Company’s directors, employees and consultants. The amount and terms of grants are determined by the Company’s board of directors. All stock options granted to date have had exercise prices equal to the fair value, as determined by the closing price as reported by the Nasdaq Global Market, of the underlying common stock on the date of grant. The contractual term of stock options is up to 10 years, and stock options are exercisable in cash or as otherwise determined by the board of directors. Generally, stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date. Performance restricted stock units (“PRSUs”) generally vest based on appreciation of the Company’s common stock to a certain price as determined by the Company’s board of directors measured using a trailing 30-day volume weighted average price of a share of the Company’s common stock. The fair value of the PRSU awards are determined using a risk neutral Monte Carlo
18
simulation valuation model. As of September 30, 2022, there were 0.6 million shares available for future issuance under the 2018 Plan.
2020 Inducement Incentive Plan
In December 2020, the Company adopted the 2020 Inducement Incentive Plan, which authorized the issuance of up to 0.4 million shares, subject to increase by approval of the Company’s board of directors, in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. In March 2022, the Company’s board of directors approved an additional 500,000 shares for the issuance under the plan. An individual who previously served as an employee or director of the Company is not eligible to receive awards under this plan. The amount and terms of grants are determined by the Company’s board of directors. As of September 30, 2022, there were 0.5 million shares available for future issuance under the 2020 Inducement Incentive Plan.
Stock Options
The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2022:
| | | | | | | | | | |
|
|
|
|
| |
|
|
| Aggregate | |
| | Number of | | Weighted- | | Weighted- | | average | ||
| | Shares under | | average | | Remaining | | Intrinsic | ||
| | Option | | Exercise Price | | Contractual | | Value | ||
| | (in thousands) | | per Option | | Life (in years) | | (in thousands) | ||
Outstanding at December 31, 2021 |
| 1,499 | | $ | 4.01 |
| |
| | |
Granted |
| — | | $ | — |
|
|
| |
|
Exercised |
| (51) | | $ | 1.01 |
| |
| |
|
Forfeited |
| (24) | | $ | 13.41 |
|
|
| |
|
Outstanding at September 30, 2022 |
| 1,424 | | $ | 3.96 |
| 7.2 |
| $ | 1,260 |
Exercisable at September 30, 2022 |
| 913 | | $ | 4.62 |
| 6.9 |
| $ | 708 |
Vested and expected to vest at September 30, 2022 |
| 1,424 | | $ | 3.96 |
| 7.2 |
| $ | 1,260 |
The Company recognized share-based compensation expense related to stock options of $0.2 million and $0.2 million for the three months ended September 30, 2022 and 2021, respectively, and $0.5 million and $0.6 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, there was $0.7 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 1.4 years. The total intrinsic value of stock options exercised during the nine months ended September 30, 2022 was $0.1 million.
19
Restricted Stock Units and Performance Restricted Stock Units
The following table summarizes the Company’s restricted stock unit and performance restricted stock unit activity for September 30, 2022:
| | | | | | | | | | |
|
| Non-vested |
| | Weighted- |
| Non-vested |
| | Weighted- |
| | Restricted | | | average | | Performance Restricted | | | average |
| | Stock Units | | | Grant-date | | Stock Units | | | Grant-date |
| | (in thousands) | | | Fair Value | | (in thousands) | | | Fair Value |
Non-vested at December 31, 2021 | | 1,729 | | $ | 7.29 |
| 395 | | $ | 6.77 |
Granted |
| 2,775 | | $ | 3.32 |
| — | | $ | — |
Vested |
| (613) | | $ | 7.64 |
| — | | $ | — |
Forfeited |
| (226) | | $ | 6.12 |
| — | | $ | — |
Non-vested at September 30, 2022 |
| 3,665 | | $ | 4.29 |
| 395 | | $ | 6.77 |
The Company recognized $2.0 million and $1.8 million in share-based compensation expense related to the restricted stock units and performance restricted stock units for the three months ended September 30, 2022 and 2021, respectively, and $6.1 million and $5.5 million the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, there was $11.0 million of unrecognized compensation cost related to non-vested restricted stock units and performance restricted stock units, which the Company expects to recognize over a weighted-average period of 1.9 years. The total fair value at the vesting date of restricted stock units and performance restricted stock units vested during the nine months ended September 30, 2022, was $2.2 million.
The Company did not grant performance restricted stock units during the period ended September 30, 2022. For the period ended December 31, 2021, the grant-date fair value of the performance restricted stock units was estimated at the time of grant using the following inputs and assumptions in the Monte Carlo simulation valuation model:
| | | |
| | December 31, 2021 |
|
Closing price of common stock | $ | 15.92 | |
Risk-free interest rate | | 1.15 | % |
Expected volatility | | 99.7 | % |
17. COMMITMENTS AND CONTINGENCIES
Legal Matters
The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company’s results of operations, financial condition, or cash flows.
18. GEOGRAPHICAL SEGMENT INFORMATION
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company currently operates in one business segment as it is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities with respect to its products or product development.
20
Geographical information
The following geographic data includes revenue generated from the Company’s third-party distributors. The Company’s revenue was generated in the following geographic regions and by product line for the periods indicated (in thousands):
| | | | | | | | | | | | | | | | | | | | | | |
| | Revenues by Geography |
| | Revenues by Geography |
| ||||||||||||||||
| | Three Months Ended September 30, |
| | Three Months Ended September 30, |
| ||||||||||||||||
| | 2022 | | 2021 |
| | 2023 | | 2022 |
| ||||||||||||
| | | | | % of | | | | | % of |
| | | | | % of | | | | | % of |
|
| | Amount | | Revenues | | Amount | | Revenues |
| | Amount | | Revenues | | Amount | | Revenues |
| ||||
| | (in thousands, except percentages) | | | (in thousands, except percentages) | | ||||||||||||||||
United States |
| $ | 16,244 |
| 98 | % | $ | 13,280 |
| 96 | % | |||||||||||
U.S. |
| $ | 17,211 |
| 96 | % | $ | 16,244 |
| 98 | % | |||||||||||
International | |
| 254 |
| 2 | % |
| 519 |
| 4 | % | |
| 673 |
| 4 | % |
| 254 |
| 2 | % |
Total revenues | | $ | 16,498 |
| 100 | % | $ | 13,799 |
| 100 | % | | $ | 17,884 |
| 100 | % | $ | 16,498 |
| 100 | % |
| | | | | | | | | | | | | | | | | | | | | | |
| | U.S. Revenues by Product Category |
| | U.S. Revenues by Product Category |
| ||||||||||||||||
| | Three Months Ended September 30, |
| | Three Months Ended September 30, |
| ||||||||||||||||
| | 2022 | | 2021 |
| | 2023 | | 2022 |
| ||||||||||||
| | | | | % of | | | | % of |
| | | | | % of | | | | % of |
| ||
|
| Amount |
| Revenues |
| Amount |
| Revenues |
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| ||||
|
| (in thousands, except percentages) | |
| (in thousands, except percentages) | | ||||||||||||||||
NeuroStar Advanced Therapy System | | $ | 3,934 | | 24 | % | $ | 2,612 | | 20 | % | | $ | 3,597 | | 21 | % | $ | 3,934 | | 24 | % |
Treatment sessions | |
| 11,864 |
| 73 | % |
| 10,259 |
| 77 | % | |
| 13,060 |
| 76 | % |
| 11,864 |
| 73 | % |
Other | |
| 446 |
| 3 | % |
| 409 |
| 3 | % | |
| 554 |
| 3 | % |
| 446 |
| 3 | % |
Total U.S. revenues | | $ | 16,244 |
| 100 | % | $ | 13,280 |
| 100 | % | | $ | 17,211 |
| 100 | % | $ | 16,244 |
| 100 | % |
| | | | | | | | | | | | | | | | | | | | | | |
| | International Revenues by Product Category |
| | International Revenues by Product Category |
| ||||||||||||||||
| | Three Months Ended September 30, |
| | Three Months Ended September 30, |
| ||||||||||||||||
| | 2022 | | 2021 |
| | 2023 | | 2022 |
| ||||||||||||
| | | | | % of | | | | | % of |
| | | | | % of | | | | | % of |
|
|
| Amount |
| Revenues |
| Amount |
| Revenues |
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| ||||
|
| (in thousands, except percentages) | |
| (in thousands, except percentages) | | ||||||||||||||||
NeuroStar Advanced Therapy System | | $ | 96 |
| 38 | % | $ | 306 |
| 59 | % | | $ | 258 |
| 38 | % | $ | 96 |
| 38 | % |
Treatment sessions | |
| 31 |
| 12 | % |
| 90 |
| 17 | % | |
| 280 |
| 42 | % |
| 31 |
| 12 | % |
Other | |
| 127 |
| 50 | % |
| 123 |
| 24 | % | |
| 135 |
| 20 | % |
| 127 |
| 50 | % |
Total International revenues | | $ | 254 |
| 100 | % | $ | 519 |
| 100 | % | |||||||||||
Total international revenues | | $ | 673 |
| 100 | % | $ | 254 |
| 100 | % |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Revenues by Geography |
| | | Revenues by Geography |
| | ||||||||||||||||
| | Nine Months Ended September 30, |
| | | Nine Months Ended September 30, |
| | ||||||||||||||||
| | 2022 | | 2021 |
| | | 2023 | | 2022 |
| | ||||||||||||
| | | | | % of | | | | | % of |
| | | | | | % of | | | | | % of |
| |
| | Amount | | Revenues | | Amount | | Revenues |
| | | Amount | | Revenues | | Amount | | Revenues |
| | ||||
| | (in thousands, except percentages) | | | | (in thousands, except percentages) | | | ||||||||||||||||
United States |
| $ | 45,893 |
| 98 | % | $ | 38,891 |
| 97 | % | | ||||||||||||
U.S. |
| $ | 49,464 |
| 97 | % | $ | 45,893 |
| 98 | % | | ||||||||||||
International | |
| 1,115 |
| 2 | % |
| 1,399 |
| 3 | % | | |
| 1,570 |
| 3 | % |
| 1,115 |
| 2 | % | |
Total revenues | | $ | 47,008 |
| 100 | % | $ | 40,290 |
| 100 | % | | | $ | 51,034 |
| 100 | % | $ | 47,008 |
| 100 | % | |
2115
| | | | | | | | | | | | | | | | | | | | | | | | |
| | U.S. Revenues by Product Category |
| | | U.S. Revenues by Product Category |
| | ||||||||||||||||
| | Nine Months Ended September 30, |
| | | Nine Months Ended September 30, |
| | ||||||||||||||||
| | 2022 | | 2021 |
| | | 2023 | | 2022 |
| | ||||||||||||
| | | | | % of | | | | % of |
| | | | | | % of | | | | % of |
| | ||
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| |
| Amount |
| Revenues |
| Amount |
| Revenues |
| | ||||
|
| (in thousands, except percentages) | | |
| (in thousands, except percentages) | | | ||||||||||||||||
NeuroStar Advanced Therapy System | | $ | 11,959 | | 26 | % | $ | 6,945 | | 18 | % | | | $ | 11,936 | | 24 | % | $ | 11,959 | | 26 | % | |
Treatment sessions | |
| 32,627 |
| 71 | % |
| 30,688 |
| 79 | % | | |
| 36,018 |
| 73 | % |
| 32,627 |
| 71 | % | |
Other | |
| 1,307 |
| 3 | % |
| 1,258 |
| 3 | % | | |
| 1,510 |
| 3 | % |
| 1,307 |
| 3 | % | |
Total U.S. revenues | | $ | 45,893 |
| 100 | % | $ | 38,891 |
| 100 | % | | | $ | 49,464 |
| 100 | % | $ | 45,893 |
| 100 | % | |
| | | | | | | | | | | | | | | | | | | | | | | |
| | International Revenues by Product Category |
| | | International Revenues by Product Category |
| ||||||||||||||||
| | Nine Months Ended September 30, |
| | | Nine Months Ended September 30, |
| ||||||||||||||||
| | 2022 | | 2021 |
| | | 2023 | | 2022 |
| ||||||||||||
| | | | | % of | | | | | % of |
| | | | | | % of | | | | | % of |
|
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| |
| Amount |
| Revenues |
| Amount |
| Revenues |
| ||||
|
| (in thousands, except percentages) | | |
| (in thousands, except percentages) | | ||||||||||||||||
NeuroStar Advanced Therapy System | | $ | 460 |
| 41 | % | $ | 797 |
| 57 | % | | | $ | 573 |
| 36 | % | $ | 460 |
| 41 | % |
Treatment sessions | |
| 214 |
| 19 | % |
| 235 |
| 17 | % | | |
| 589 |
| 38 | % |
| 214 |
| 19 | % |
Other | |
| 441 |
| 40 | % |
| 367 |
| 26 | % | | |
| 408 |
| 26 | % |
| 441 |
| 40 | % |
Total International revenues | | $ | 1,115 |
| 100 | % | $ | 1,399 |
| 100 | % | | | $ | 1,570 |
| 100 | % | $ | 1,115 |
| 100 | % |
19. SEVERANCE14. DEBT
The Company entered into transition agreements outliningfollowing table presents the separation with certain former employees duringcomposition of debt as of September 30, 2023 and December 31, 2022 (in thousands):
| | | | | | | |
| | September 30, | | December 31, | | ||
|
| 2023 |
| 2022 | | ||
Outstanding principal | | $ | 37,500 | | $ | 35,000 | |
Accrued final payment fees | |
| 1,856 | |
| 1,925 | |
Less debt discounts | |
| (2,505) | |
| (971) | |
Total debt, net | |
| 36,851 | |
| 35,954 | |
Less current portion | |
| — | |
| (13,125) | |
Long-term debt, net | | $ | 36,851 | | $ | 22,829 | |
For the periodthree months ended September 30, 2022 and 2021. In connection with these agreements,2023, the Company recorded $0.0 million and $0.3recognized interest expense of $1.2 million, of charges in salary, payroll taxwhich $1.1 million was cash and bonus expenses for$0.1 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the three months ended September 30, 2022, and 2021, respectively,the Company recognized interest expense of $1.1 million, of which $0.9 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and $0.5 million foraccrual of final payment fees.
For the nine months ended September 30, 20222023, the Company recognized interest expense of $3.6 million, of which $3.1 million was cash and 2021, respectively.$0.5 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the nine months ended September 30, 2022, the Company recognized interest expense of $3.0 million, of which $2.5 million was cash and 2021, $0.4$0.5 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.
Solar Credit Facility
Solar Facility Fourth and Fifth Amendments
16
On March 29, 2023, the Company entered into a fourth amendment (the “Solar Fourth Amendment”) to the Loan and Security Agreement dated March 2, 2020 with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent and other lenders as defined in the agreement (the “Lenders”; such agreement, as amended, the “Solar Facility”). On September 29, 2023, the Company entered into a fifth amendment (the “Solar Fifth Amendment”) to the Solar Facility.
The Solar Facility permits the Company to borrow up to $60.0 million in three tranches of term loans, a “Term A Loan” in an aggregate amount of $35.0 million, a “Term B Loan” in an aggregate amount of $2.5 million, and $1.1 million of termination benefits were paid associateda “Term C Facility” (collectively with the terminationTerm A Loan and Term B Loan, the “Loans”) in an aggregate principal amount equal to $22.5 million. The Term A Loan was fully drawn prior to the effectiveness of the employeesSolar Fourth Amendment. On March 29, 2023, the Company borrowed an amount of $2.5 million under the Term B Loan. On October 3, 2023, the Company borrowed an amount of $22.5 million under the Term C Facility (the “Term C Funding Date”). The maturity date of the Loans is March 29, 2028. Prior to the effectiveness of the Solar Fourth Amendment, the maturity date of the Term A Loan was February 28, 2025.
The Loans accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and charged against this liability. is equal to the greater of 5.65% plus (a) 3.95% or (b) daily simple SOFR for a term of one month. Only interest is required to be paid on the Loans until March 1, 2026. Prior to the effectiveness of the Solar Fourth Amendment, the interest only period with respect to the Term A Loan expired on March 1, 2023. Commencing April 1, 2026, the Company will be required to make monthly payments of principal and interest on the Loans.
In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar upon the earlier of prepayment, acceleration or the maturity date of the Loans equal to 4.95% of the principal amount of the term loans actually funded. If the Company prepays the Loans prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of the Term C Funding Date, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of the Term C Funding Date, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of the Term C Funding Date.
The Company is also required to pay Solar an exit fee upon the occurrence of (a) any liquidation, dissolution or winding up of the Company, (b) any transaction that results in a person obtaining control over the Company, (c) the Company achieving $100 million in trailing twelve-month net product revenue or (d) the Company achieving $125 million in trailing twelve-month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 2% of the principal amount of the term loans actually funded. The exit fee for achieving either $100 million or $125 million in trailing twelve-month net product revenue is equal to 1% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 2% of the principal amount of the term loans actually funded. The exit fee is capped at 2% of the principal amount of the term loans actually funded.
In connection with entering into the Solar Fourth Amendment and pursuant to the prepayment provisions of the previous Solar facility, the Company paid Solar a final payment fee of $1.2 million on March 29, 2023.
The Solar Fifth Amendment (a) permitted the Company to draw on the $22.5 million Term C Facility, and (b) revised the required testing levels of the net product revenue and minimum liquidity covenants for certain testing periods.
17
As of September 30, 20222023, the Company was in compliance with all covenants in the Solar Facility, and December 31, 2021, $0.0 million and $0.1 million, respectively, remainthe Company expects to be in accrued liabilities forcompliance with the unpaid portion of the separation benefits.covenants going forward.
20. RISKS AND UNCERTAINTIES15. COMMON STOCK
Information About Significant CustomersCommon Stock
Significant customers are those which represent more than 10%The following table summarizes the total number of shares of the Company’s total revenue or are considered significant based on combinationcommon stock issued and reserved for issuance as of quantitativeSeptember 30, 2023 and qualitative factors during the periods. For each significant customer, revenue as a percentage of total revenue was as followsDecember 31, 2022 (in thousands, except for percentages)thousands):
| | | | | | | | | | | | | | | | |
| | Nine Months Ended September 30, |
|
| September 30, 2023 |
| December 31, 2022 | | ||||||||
| | 2022 | | 2021 |
| |||||||||||
| | | | | % of | | | | | % of |
| |||||
| | Amount | | Revenues | | Amount | | Revenues |
| |||||||
| | (in thousands, except percentages) | | |||||||||||||
Customer 1 |
| $ | 9,183 |
| 20 | % | $ | 8,759 |
| 22 | % | |||||
Total | | $ | 9,183 |
| 20 | % | $ | 8,759 |
| 22 | % | |||||
Shares of common stock issued |
| 28,902 |
| 27,268 | | |||||||||||
Shares of common stock reserved for issuance for: |
|
|
|
| | |||||||||||
Common stock warrants outstanding |
| 41 |
| 61 | | |||||||||||
Stock options outstanding |
| 1,271 |
| 1,301 | | |||||||||||
Restricted stock units outstanding |
| 3,634 |
| 3,901 | | |||||||||||
Shares available for grant under stock incentive plans |
| 893 |
| 1,140 | | |||||||||||
Shares available for sale under employee stock purchase plan |
| 1,335 |
| 1,063 | | |||||||||||
Total shares of common stock issued and reserved for issuance |
| 36,076 |
| 34,734 | |
Common Stock Warrants
The following tables summarize the Company’s outstanding common stock warrants as of September 30, 2023, and December 31, 2022:
| | | | | |
September 30, 2023 |
|
| |
|
|
Warrants |
|
| |
|
|
Outstanding | | | | | |
(in thousands) | | Exercise Price | | Expiration Date | |
20 | | $ | 9.73 |
| Mar-2024 |
21 | | $ | 9.73 |
| Dec-2024 |
41 | |
|
|
|
|
| | | | | |
December 31, 2022 |
|
| |
|
|
Warrants |
|
| |
|
|
Outstanding | | | | | |
(in thousands) | | Exercise Price | | Expiration Date | |
20 | | $ | 9.73 |
| Aug-2023 |
20 | | $ | 9.73 |
| Mar-2024 |
21 | | $ | 9.73 |
| Dec-2024 |
61 | |
|
|
|
|
16. LOSS PER SHARE
The Company’s basic loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. The Company’s restricted stock awards (non-vested shares) are issued and outstanding at the time of grant but are excluded from the Company’s computation of weighted-average shares outstanding in the determination of basic loss per share until vesting occurs.
2218
Accounts receivableA net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding related to these customersand the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options, non-vested restricted stock units and non-vested performance restricted stock units (“PRSUs”) using the treasury stock method, along with the effect, if any, from the potential conversion of outstanding securities, such as convertible preferred stock.
The following potentially dilutive securities outstanding as of September 30, 2023 and 2022 washave been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):
| | | | |
| | September 30, | ||
|
| 2023 |
| 2022 |
Stock options | | 1,271 | | 1,424 |
Non-vested PRSUs |
| 395 |
| 395 |
Non-vested restricted stock units |
| 3,239 |
| 3,665 |
Common stock warrants |
| 41 |
| 75 |
17. SHARE-BASED COMPENSATION
The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and nine months ended September 30, 2023 and 2022 is as follows (in thousands):
| | | | | | | | | | | | | | | |
| | | September 30, |
| Three Months Ended September 30, | | Nine Months Ended September 30, | ||||||||
| | | 2022 | | 2023 |
| 2022 |
| 2023 |
| 2022 | ||||
Customer 1 |
| $ | 4,886 | ||||||||||||
Total accounts receivable | | $ | 4,886 | ||||||||||||
Cost of revenues | | $ | 38 | | $ | 35 | | $ | 109 | | | 94 | |||
Sales and marketing | |
| 590 | |
| 1,074 | |
| 1,946 | | | 3,258 | |||
General and administrative | |
| 1,052 | |
| 939 | |
| 3,134 | | | 2,950 | |||
Research and development | |
| 175 | |
| 130 | |
| 504 | | | 331 | |||
Total | | $ | 1,855 | | $ | 2,178 | | $ | 5,693 | | $ | 6,633 |
2018 Equity Incentive Plan
In June 2018, the Company adopted the 2018 Equity Incentive Plan, (the “2018 Plan”), which authorized the issuance of up to 1.4 million shares, subject to an annual 4% increase based on the number of shares of common stock outstanding, in the form of restricted stock, stock appreciation rights and stock options to the Company’s directors, employees and consultants. The amount and terms of grants are determined by the Company’s board of directors. All stock options granted to date have had exercise prices equal to the fair value, as determined by the closing price as reported by the Nasdaq Global Market, of the underlying common stock on the date of grant. The contractual term of stock options is up to 10 years, and stock options are exercisable in cash or as otherwise determined by the Company’s board of directors. Generally, stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock units generally vest ratably in three equal installments on the first, second and third anniversaries of the grant date. PRSUs generally vest based on appreciation of the Company’s common stock to a certain price as determined by the Company’s board of directors measured using a trailing 30-day volume-weighted average price of a share of the Company’s common stock. The fair value of the PRSU awards are determined using a risk neutral Monte Carlo simulation valuation model. As of September 30, 2023, there were 0.6 million shares available for future issuance under the 2018 Plan.
19
2020 Inducement Incentive Plan
In December 2020, the Company adopted the 2020 Inducement Incentive Plan (the “2020 Plan”), which authorized the issuance of up to 0.4 million shares, subject to increase by approval of the Company’s board of directors, in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards to eligible employees who satisfy the standards for inducement grants under Nasdaq Global Market rules. In March 2022, the Company’s board of directors approved an additional 0.5 million shares for the issuance under the 2020 Plan. An individual who previously served as an employee or director of the Company is not eligible to receive awards under the 2020 Plan. The amount and terms of grants are determined by the Company’s board of directors. As of September 30, 2023, there were 0.3 million shares available for future issuance under the 2020 Plan.
Stock Options
The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2023:
| | | | | | | | | | |
|
|
|
|
| |
| Weighted- |
| Aggregate | |
| | Number of | | Weighted- | | average | | average | ||
| | Shares under | | average | | Remaining | | Intrinsic | ||
| | Option | | Exercise Price | | Contractual | | Value | ||
| | (in thousands) | | per Option | | Life (in years) | | (in thousands) | ||
Outstanding at December 31, 2022 |
| 1,301 | | $ | 4.07 |
| |
| | |
Granted |
| — | | $ | — |
|
|
| |
|
Exercised |
| — | | $ | — |
| |
| |
|
Forfeited |
| (30) | | $ | 11.67 |
|
|
| |
|
Outstanding at September 30, 2023 |
| 1,271 | | $ | 3.89 |
| 6.3 |
| $ | 3 |
Exercisable at September 30, 2023 |
| 1,058 | | $ | 4.27 |
| 6.3 |
| $ | 3 |
Vested and expected to vest at September 30, 2023 |
| 1,271 | | $ | 3.89 |
| 6.3 |
| $ | 3 |
The Company recognized share-based compensation expense related to stock options of $0.1 million and $0.2 million for the three months ended September 30, 2023 and 2022, respectively, and $0.3 million and $0.5 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $0.2 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 0.8 years.
For the nine months ended September 30, 2023 the Company did not grant stock options.
Restricted Stock Units and Performance Restricted Stock Units
The following table summarizes the Company’s restricted stock unit and PRSU activity for September 30, 2023:
| | | | | | | | | | |
|
| Non-vested |
| | Weighted- |
| Non-vested |
| | Weighted- |
| | Restricted | | | average | | PRSUs | | | average |
| | Stock Units | | | Grant-date | | | | | Grant-date |
| | (in thousands) | | | Fair Value | | (in thousands) | | | Fair Value |
Non-vested at December 31, 2022 | | 3,506 | | $ | 4.29 |
| 395 | | $ | 6.77 |
Granted |
| 1,640 | | $ | 4.73 |
| — | | $ | — |
Vested |
| (1,634) | | $ | 4.38 |
| — | | $ | — |
Forfeited |
| (273) | | $ | 5.08 |
| — | | $ | — |
Non-vested at September 30, 2023 |
| 3,239 | | $ | 4.41 |
| 395 | | $ | 6.77 |
20
The Company recognized $1.8 million and $2.0 million in share-based compensation expense related to the restricted stock units and PRSUs for the three months ended September 30, 2023 and 2022, respectively, and $5.3 million and $6.1 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $10.0 million of unrecognized compensation cost related to non-vested restricted stock units and PRSUs, which the Company expects to recognize over a weighted-average period of 1.8 years. The total fair value at the vesting date of restricted stock units and PRSUs vested during the nine months ended September 30, 2023 was $8.3 million.
The Company did not grant PRSUs during the nine months ended September 30, 2023.
18. COMMITMENTS AND CONTINGENCIES
Legal Matters
The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company’s results of operations, financial condition, or cash flows.
19. SEGMENT INFORMATION
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company currently operates in one business segment as it is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities with respect to its products or product development.
20. GOVERNMENT ASSISTANCE
Employee Retention Credit
The Coronavirus Aid, Relief and Economic Security Act provided an Employee Retention Credit (the “ERC”), which was a refundable tax credit related to certain payroll taxes. The Company applied the grant model and determined that the criteria for recognition of the ERC was met during the quarter ended June 30, 2023 based on the Company’s determination of eligibility and filing of the ERC claim. As of September 30, 2023, the $2.9 million ERC receivable is reported within prepaid expenses and other current assets on the Company’s balance sheet. The credit is reported within other income, net in the Company’s statements of operations for the nine months ended September 30, 2023.
2321
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim financial statements and related notes thereto included elsewhere herein. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended.amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to: the ongoing impact of the novel coronavirus, or COVID-19, pandemic on general political and economic uncertainty, including as a result of efforts by governmental authorities to mitigate the COVID-19 pandemic and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; our ability to execute our business continuity as well as our operational and budget plans in light of the COVID-19 pandemic; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications; developments in regulation in the United StatesU.S. and other applicable jurisdictions; and the impacts on our operational and budget plans due to inflation. For a discussion of these and other related risks, please refer to our recent SEC filings which are available on the SEC’s website at www.sec.gov.www.sec.gov, including those described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10 K filed with the SEC, on March 7, 2023. These forward-looking statements are based on our expectations and assumptions as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this Quarterly Report on Form 10-Q as a result of new information, future events or changes in our expectations.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC, on March 8, 2022. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
24
Overview
We are a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. Our first commercial product, the NeuroStar®NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA to treat adult patients with major depressive disorder, or MDD thatwho have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode. OurThe NeuroStar Advanced Therapy system was also cleared in 2022 by the FDA to treat people suffering from obsessive-compulsive disorder as well as for the treatment of anxious depression. NeuroStar Advanced TherapySystem is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The NeuroStar Advanced Therapy System is safe, clinically effective, reproducible and precise and we believe is supported by the largest clinical data set of any competing TMS system. We believe we are the market leader in TMS therapy based on over 141,070162,575 global patients treated with over 5.15.9 million of our Treatment Sessionstreatment sessions through September 30, 2022.2023. We generated revenues of $16.5$17.9 million and $13.8$16.5 million for the three months ended September 30, 20222023 and 2021,2022, respectively, and $47.0$51.0 million and $40.3$47.0 million for the nine months ended September 30, 2023 and 2022, and 2021, respectively.
22
We designed the NeuroStar Advanced Therapy System as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of other treatment options. We generate revenues from initial capital sales of our systems, recurring Treatment Sessionstreatment sessions and service and repair and extended warranty contracts. We derive the majority of our revenues from recurring Treatment Sessions.treatment sessions. For the three months ended September 30, 2022,2023 revenues from sales of our Treatment Sessionstreatment sessions and NeuroStar Advanced Therapy Systems represented 76% and 21% of our U.S. revenues, respectively, and for the nine months ended September 30, 2023 revenues from sales of our treatment sessions and NeuroStar Therapy Systems represented 73% and 24% of our U.S. revenues, respectively, and 71% and 26% for the nine months ended September 30, 2022 and 2021, respectively.
We currently sell our NeuroStar Advanced Therapy System and recurring Treatment Sessionstreatment sessions in the United StatesU.S. with the collaborative support of our 198211 employees as of September 30, 2022.2023. Our sales force targets an estimated 50,000 psychiatrists across 26,000 psychiatric practices in the United States,U.S., based on a 2020 data set from Symphony Health and our own internal estimates that treat approximately 42% of the total MDD patients in the United StatesU.S. who meet our labeled indication and are insured. Some of our customers have andpurchased or may purchase more than one NeuroStar Advanced Therapy System. Based on our commercial data, we believe our customers can recoup their initial capital investment in our system by providing a standard course of treatment to approximately 12 patients. We believe our customers can generate approximately $8,500 of average revenue per patient for a standard course of treatment, which may provide meaningful incremental income to their practices. We have a diverse customer base, including psychiatrists in group psychiatric practices, pain management physicians and other medical professionals in the United States.U.S. For the three and nine months ended September 30, 2022,2023, one customer accounted for more than 10% of our revenues.
We market our products in a few select markets outside the United StatesU.S. through independent distributors. International revenues represented 2%4% and 4%2% of our total revenues for the three months ended September 30, 20222023 and 2021,2022, respectively, and 2%3% and 3%2% for the nine months ended September 30, 20222023 and 2021,2022, respectively. In October 2017, we entered into an exclusive distribution agreement with Teijin Pharma Limited or Teijin,(“Teijin”), for the distribution of our NeuroStar Advanced Therapy Systems and Treatment Sessionstreatment sessions to customers who will treat patients with MDD in Japan. We received regulatory approval for our system in Japan in September 2017 and we received the initial reimbursement of JPY 12,000 per Treatment Session,treatment session, which went into effect on June 1, 2019. We expect our international revenues to increase over time as a percentage of our total revenues as we grow system placements and utilization in Japan.
Our research and development efforts are focused on the following: hardware and software product developments and enhancements of our NeuroStar Advanced Therapy System and clinical developments relating to additional indications. We outsource the manufacture of components of our NeuroStar Advanced
25
Therapy Systems that are produced to our specifications, and individual components are either shipped directly from our third-party contract manufacturers to our customers or consolidated into pallets at our Malvern, Pennsylvania facility prior to shipment. Final installation of these systems occurs at the customer site.
Our total revenues increased by $2.7$1.4 million, or 20%8%, from $13.8 million for the three months ended September 30, 2021 to $16.5 million for the three months ended September 30, 2022 and increased by $6.7 million, or 17%, from $40.3to $17.9 million for the ninethree months ended September 30, 2021 to2023 and increased by $4.0 million, or 9%, from $47.0 million for the nine months ended September 30, 2022.2022 to $51.0 million for the nine months ended September 30, 2023. For the three and nine months ended September 30, 2022,2023, our U.S. revenues were $17.2 million and $49.5 million, respectively, compared to $16.2 million and $45.9 million compared to $13.3 million and $38.9 million for three and nine months ended September 30, 2021,2022, respectively, which represents an increase of 22%6% and 18%8% respectively, period over period. The increase was primarily attributable to an increase in Treatment SessionU.S NeuroStar Advanced Therapy System sales period over period. We incurred net losses of $7.6$9.4 million and $28.9$24.8 million for the three and nine months ended September 30, 20222023 compared to net losses of $8.2$7.6 million and $23.6$28.9 million for three and nine months ended September 30, 2021.2022. We expect to continue to incur losses for the next several years as we invest in our commercial organization to support our planned sales growth and while continuing to invest in our pipeline indications. As of September 30, 2022,2023, we had an accumulated deficit of $337.6$370.7 million.
COVID-19
23
Throughout 2020, 2021 and the nine months ended September 30, 2022, the Company experienced a material impact to revenue, particularly with regards to U.S. Treatment Session revenues as a result of the COVID-19 pandemic. The Company expects that capital equipment sales and Treatment Session revenues will continue to be impacted by the pandemic as customers defer capital purchase decisions and delay new patient treatment starts. System utilization has also declined compared to pre-COVID-19 projections.Global Economic Conditions
We have monitored the impact of the COVID-19 pandemic on all aspects of our businessare continuing to closely monitor macroeconomic impacts, including, but not limited to, developments affecting financial institutions, inflationary and geographies, including how it has and will continue to impact the Company’s customers, supply chain, employees and other business partners. While we experienced significant disruptions in the current period and the nine months ended September 30, 2022 from the COVID-19 pandemic, we are unable to predict the ultimate impact that the COVID-19 pandemic may havepotential recessionary pressures, on our financial condition,business, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the ongoing pandemic, the actions taken to contain the pandemic or mitigate itsfinancial results. We currently believe these conditions have no material impact and the direct and indirect economic effects of the pandemic, vaccination rates and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity.
The situation surrounding the COVID-19 pandemic remains fluid, and we are actively managing our response in collaboration with business partners and assessing potential impacts to our financial position and operating results, as well as potential adverse developments in our business. For further information regarding the impact of COVID-19 on the Company, see Item 1A titled “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021.at this time.
Components of Our Results of Operations
Revenues
To date, we have generated revenues primarily from the capital portion of our business and related sales and rentals of the NeuroStar Advanced Therapy System and the recurring revenues from our sale of Treatment Sessionstreatment sessions in the United States.U.S.
NeuroStar Advanced Therapy System Revenues. NeuroStar Advanced Therapy System revenues consist primarily of sales or rentals of a capital component, including upgrades to the equipment attributable to the initial sale of the system. NeuroStar Advanced Therapy Systems can be purchased outright or on a rent-to-own basis by certain customers.
26
Treatment Session Revenues. Treatment Sessionsession revenues primarily include sales of NeuroStar Treatment SessionsAdvanced Therapy System treatment sessions and SenStar treatment links. The NeuroStar Treatment Sessionstreatment sessions are access codes that are delivered electronically in the United States.U.S. The SenStar treatment links are disposable units containing single-use access codes that are sold and used outside the United States.U.S. Access codes are purchased separately by our customers, primarily on an as-needed basis, and are required by the NeuroStar Advanced Therapy System in order to deliver Treatment Sessions.treatment sessions.
Other Revenues. Other revenues are derived primarily from service and repair and extended warranty contracts and D-tect sales with our existing customers.
We refer you to the section titled “Critical Accounting Policies and Use of Estimates—Revenue Recognition” appearing in our Form 10-K filed with the SEC on March 8, 2022.7, 2023. We also refer you to “Note 3. Summary of Significant Accounting Policies.”
Cost of Revenues and Gross Margin
Cost of revenues primarily consists of the costs of components and products purchased from our third-party contract manufacturers of our NeuroStar Advanced Therapy Systems as well as the cost of treatment packs for individual Treatment Sessions.treatment sessions. We use third-party contract manufacturing partners to produce the components for and assemble the completed NeuroStar Advanced Therapy Systems. Cost of revenues also includes costs related to personnel, warranty, shipping, and our operations and field service departments. We expect our total cost of revenues to increase to the extent our revenues grow.
Our gross profit is calculated by subtracting our cost of revenues from our revenues. We calculate our gross margin as our gross profit divided by our revenues. Our gross margin has been and will continue to be affected by a variety of factors, primarily product sales mix, pricing and third-party contract manufacturing costs. Our gross margins on revenues from sales of NeuroStar Advanced Therapy Systems are lower than our gross margins on revenues from sales of Treatment Sessionstreatment sessions and, as a result, the sales mix between NeuroStar Advanced Therapy Systems and Treatment Sessionstreatment sessions can affect the gross margin in any reporting period.
Sales and Marketing Expenses
Sales and marketing expenses consist of market researchmarketing programs and commercial activities related to the sale of our NeuroStar Advanced Therapy Systems and Treatment Sessionstreatment sessions and salaries and related benefits, sales
24
commissions and share-based compensation for employees focused on these efforts. Other significant sales and marketing costs include conferences and trade shows, promotional and marketing activities, including direct and online marketing, practice support programs and radiodigital media campaigns, travel and training expenses.
We anticipate that our sales and marketing expenses will increase for the remainder of 2022decrease in 2023 compared to same-period 20212022 expenses as we continuedue in part to execute on our growth initiatives and expand our business in the United States.termination of the one-time 2022 sales equity match incentive.
General and Administrative Expenses
General and administrative expenses consist primarily of personnel expenses, including salaries and related benefits, share-based compensation and travel expenses, for employees in executive, finance, information technology (“IT”), legal and human resource functions. General and administrative expenses also include the cost of insurance, outside legal fees, accounting and other consulting services, audit fees from our independent registered public accounting firm, board of directors’ fees and other administrative costs, such as corporate facility costs, including rent, utilities, depreciation and maintenance not otherwise included in cost of revenues.
27
We anticipate that our general and administrative expenses in 2023 will remain flat compared to our 20212022 expenses.
Research and Development Expenses
Research and development expenses consist primarily of personnel expenses, including salaries and related benefits and share-based compensation for employees in clinical development, product development, regulatory and quality assurance functions, as well as expenses associated with outsourced professional scientific development services and costs of investigative sites and consultants that conduct our preclinical and clinical development programs. We typically use our employee, consultant and infrastructure resources across our research and development programs.
We plan to incur additional research and development expenses infor the near future as we expect to continue our development of TMS Therapytherapy for the treatment of additional patient populations and new indications related to neurohealth disorders, as well as for various hardware and software development projects. As a result, we expect our research and development expenses to increase for the remainder of 2022during 2023 compared to same-period 2021our 2022 expenses.
Interest Expense
Interest expense consists of cash interest payable under our credit facility and non-cash interest attributable to the accrual of final payment fees and the amortization of deferred financing costs related to our indebtedness.
Other Income, Net
Other income, net consists primarily of the ERC and interest income earned on our money market account balances and note receivables.notes receivable.
25
Results of Operations
Comparison of the three months ended September 30, 20222023 and 20212022
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | | | | |
| | Three Months Ended | | | | | |
| ||||||||
| | September 30, | | Increase / (Decrease) | | | September 30, | | Increase / (Decrease) | | ||||||||||||||
|
| 2022 |
| 2021 |
| Dollars |
| Percentage |
|
| 2023 |
| 2022 |
| Dollars |
| Percentage |
| ||||||
| | (in thousands, except percentages) |
| | (in thousands, except percentages) |
| ||||||||||||||||||
Revenues | | $ | 16,498 | | $ | 13,799 | | $ | 2,699 |
| 20 | % | | $ | 17,884 | | $ | 16,498 | | $ | 1,386 |
| 8 | % |
Cost of revenues | |
| 3,570 | |
| 3,144 | |
| 426 |
| 14 | % | |
| 6,120 | |
| 3,570 | |
| 2,550 |
| 71 | % |
Gross Profit | |
| 12,928 | |
| 10,655 | |
| 2,273 |
| 21 | % | |
| 11,764 | |
| 12,928 | |
| (1,164) |
| (9) | % |
Gross Margin | |
| 78.4 | % |
| 77.2 | % |
| |
|
| | |
| 65.8 | % |
| 78.4 | % |
| |
|
| |
| |
| | | | | | | | | | | |
| | | | | | | | | | |
Operating expenses: | |
|
| |
|
| |
| |
|
| | |
|
| |
|
| |
| |
|
| |
Sales and marketing | |
| 11,643 | |
| 9,827 | |
| 1,816 |
| 18 | % | |
| 12,141 | |
| 11,643 | |
| 498 |
| 4 | % |
General and administrative | |
| 6,391 | |
| 6,435 | |
| (44) |
| (1) | % | |
| 6,339 | |
| 6,391 | |
| (52) |
| (1) | % |
Research and development | |
| 2,348 | |
| 1,575 | |
| 773 |
| 49 | % | |
| 2,155 | |
| 2,348 | |
| (193) |
| (8) | % |
Total operating expenses | |
| 20,382 | |
| 17,837 | |
| 2,545 | | 14 | % | |
| 20,635 | |
| 20,382 | |
| 253 | | 1 | % |
Loss from Operations | |
| (7,454) | | | (7,182) | |
| (272) |
| (4) | % | |
| (8,871) | | | (7,454) | |
| (1,417) |
| (19) | % |
Other (income) expense: | |
| | |
|
| |
| |
|
| | |
| | |
|
| |
| |
|
| |
Interest expense | |
| 1,061 | |
| 993 | |
| 68 |
| 7 | % | |
| 1,184 | |
| 1,061 | |
| 123 |
| 12 | % |
Other income, net | |
| (906) | |
| (24) | |
| (882) |
| 3,675 | % | |
| (664) | |
| (906) | |
| 242 |
| (27) | % |
Net Loss | | $ | (7,609) | | $ | (8,151) | | $ | 542 |
| 7 | % | | $ | (9,391) | | $ | (7,609) | | $ | (1,782) |
| (23) | % |
28
| | | | | | | | | | | | | | | | | | | | | | |
| | Revenues by Geography |
| | Revenues by Geography |
| ||||||||||||||||
| | Three Months Ended September 30, |
| | Three Months Ended September 30, |
| ||||||||||||||||
| | 2022 | | 2021 |
| | 2023 | | 2022 |
| ||||||||||||
| | | | | % of | | | | | % of |
| | | | | % of | | | | | % of |
|
|
| Amount |
| Revenues |
| Amount |
| Revenues |
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| ||||
| | (in thousands, except percentages) |
| | (in thousands, except percentages) |
| ||||||||||||||||
United States | | $ | 16,244 | | 98 | % | $ | 13,280 | | 96 | % | |||||||||||
U.S. | | $ | 17,211 | | 96 | % | $ | 16,244 | | 98 | % | |||||||||||
International | |
| 254 |
| 2 | % |
| 519 |
| 4 | % | |
| 673 |
| 4 | % |
| 254 |
| 2 | % |
Total revenues | | $ | 16,498 |
| 100 | % | $ | 13,799 |
| 100 | % | | $ | 17,884 |
| 100 | % | $ | 16,498 |
| 100 | % |
| | | | | | | | | | | | | | | | | | | | | | |
| | U.S. Revenues by Product Category |
| | U.S. Revenues by Product Category |
| ||||||||||||||||
| | Three Months Ended September 30, |
| | Three Months Ended September 30, |
| ||||||||||||||||
| | 2022 | | 2021 |
| | 2023 | | 2022 |
| ||||||||||||
| | | | | % of | | | | | % of |
| | | | | % of | | | | | % of |
|
|
| Amount |
| Revenues |
| Amount |
| Revenues |
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| ||||
| | (in thousands, except percentages) |
| | (in thousands, except percentages) |
| ||||||||||||||||
NeuroStar Advanced Therapy System | | $ | 3,934 | | 24 | % | $ | 2,612 | | 20 | % | | $ | 3,597 | | 21 | % | $ | 3,934 | | 24 | % |
Treatment sessions | |
| 11,864 |
| 73 | % |
| 10,259 |
| 77 | % | |
| 13,060 |
| 76 | % |
| 11,864 |
| 73 | % |
Other | |
| 446 |
| 3 | % |
| 409 |
| 3 | % | |
| 554 |
| 3 | % |
| 446 |
| 3 | % |
Total U.S. revenues | | $ | 16,244 |
| 100 | % | $ | 13,280 |
| 100 | % | | $ | 17,211 |
| 100 | % | $ | 16,244 |
| 100 | % |
Revenues
Total revenue for the three months ended September 30, 20222023 was $16.5$17.9 million, an increase of 20%8% compared to the three months ended September 30, 20212022 revenue of $13.8$16.5 million. During the quarter, total U.S. revenue increased by 22%6% and international revenue decreasedincreased by 51%165% over the prior year quarter. The U.S. revenue growth was primarily driven by an increase in Treatment sessions sales and the declinetreatment session sales. The increase in international revenue was primarily driven by a decreasean increase in international NeuroStar Advanced Therapy SystemsSystem sales and treatment session sales.
U.S. NeuroStar Advanced Therapy System revenue for the three months ended September 30, 20222023 was $3.9$3.6 million, an increasea decrease of 50%9% compared to the three months ended September 30, 20212022 revenue of $2.6 $3.9
26
million. For the three months ended September 30, 20222023 and 2021,2022, the Company sold 4943 and 3349 systems, respectively, that were recognized as NeuroStar Advanced Therapy System capital revenue during each period. Additionally, for the three months ended September 30, 2022 and 2021, the Company executed 1 and 7 operating lease agreements, respectively,agreement that contributed to operating lease revenue.
U.S. Treatment Sessiontreatment session revenue for the three months ended September 30, 20222023 was $11.9$13.1 million, an increase of 16%10% compared to the three months ended September 30, 20212022 revenue of $10.3$11.9 million. The revenue growth was primarily driven by an increase in the number of accounts utilizing our PHQ 10 tool. As a result, our treatment session volume in our local per click accounts, those utilizing our PHQ 10 tool increased 36.9% compared to third quarter of 2021.and utilization over the prior year quarter.
Cost of Revenues and Gross Margin
Cost of revenues increased by $0.5$2.5 million, or 14%71%, from $3.1 million for the three months ended September 30, 2021 to $3.6 million for the three months ended September 30, 2022. Gross margin increased from 77.2%2022 to $6.1 million for the three months ended September 30, 20212023. This increase was primarily due to the recording of a $1.9 million inventory impairment for specialized component parts secured for discontinued NeuroStar Advanced Therapy Systems for which costs exceed net realizable value. Gross margin decreased from 78.4% for the three months ended September 30, 2022.2022 to 65.8% for the three months ended September 30, 2023. The increasedecrease in gross margin was primarilydriven by the one-time inventory impairment, higher operational costs related to our transition to a result of a change innew third-party contract manufacturing partner and software amortization expense from the latest product mix compared to the prior year quarter.release.
Sales and Marketing Expenses
Sales and marketing expenses increased by $1.8$0.5 million, or 18%4%, from $9.8 million for the three months ended September 30, 2021 to $11.6 million for the three months ended September 30, 2022.2022 to $12.1 million for the three months ended September 30, 2023. The increase was expected and primarily due to newincreased spending on co-op marketing initiative related costs, including trade shows, digital paid
29
media costs and market research, and sales personnel expenses related to salary, benefits, commissions and share-based compensation incurredgrowth in the current period versus the prior year quarter.that program.
General and Administrative Expenses
General and administrative expenses remained materially consistent from $6.4 million for the three months ended September 30, 20212022 to $6.3 million for the three months ended September 30, 2022.2023.
Research and Development Expenses
Research and development expenses increaseddecreased by $0.7$0.1 million, or 49%8%, from $1.6 million for the three months ended September 30, 2021 to $2.3 million for the three months ended September 30, 2022. The increase was primarily due2022 to a reduction in product development costs related to the capitalization of certain of the Company’s software project costs, which was partially offset by an increase in clinical development costs versus the prior year quarter.
Interest Expense
Interest expense remained constant at $1.0$2.2 million for the three months ended September 30, 2022.2023. The decrease was primarily due to higher software capitalization, related to the latest development of the NeuroStar system.
Other Income, NetInterest Expense
Other income, netInterest expense increased by $0.9$0.1 million, or 12%, from $0.02$1.1 million for the three months ended September 30, 20212022 to $1.2 million for the three months ended September 30, 2023 due to interest rate and debt balance increases.
Other Income, Net
Other income, net decreased by $0.2 million, or 27%, from $0.9 million for the three months ended September 30, 2022 to $0.7 million for the three months ended September 30, 2023, primarily as a result of increaseddecreased interest income earned on the Company’s note receivables.money market accounts which was partially offset by increase in notes receivable interest.
3027
Comparison of the nine months ended September 30, 20222023 and 20212022
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Nine Months Ended | | | | | |
| | | Nine Months Ended | | | | | |
| | ||||||||
| | September 30, | | Increase / (Decrease) | | | | September 30, | | Increase / (Decrease) | | | ||||||||||||||
|
| 2022 |
| 2021 |
| Dollars |
| Percentage |
| |
| 2023 |
| 2022 |
| Dollars |
| Percentage |
| | ||||||
| | (in thousands, except percentages) |
| | | (in thousands, except percentages) |
| | ||||||||||||||||||
Revenues | | $ | 47,008 | | $ | 40,290 | | $ | 6,718 |
| 17 | % | | | $ | 51,034 | | $ | 47,008 | | $ | 4,026 |
| 9 | % | |
Cost of revenues | |
| 11,093 | |
| 8,115 | |
| 2,978 |
| 37 | % | | |
| 15,100 | |
| 11,093 | |
| 4,007 |
| 36 | % | |
Gross Profit | |
| 35,915 | |
| 32,175 | |
| 3,740 |
| 12 | % | | |
| 35,934 | |
| 35,915 | |
| 19 |
| 0 | % | |
Gross Margin | |
| 76.4 | % |
| 79.9 | % |
| |
|
| | | |
| 70.4 | % |
| 76.4 | % |
| |
|
| | |
| |
| | | | | | | | | | | | |
| | | | | | | | | | | |
Operating expenses: | |
|
| |
|
| |
| |
|
| | | |
|
| |
|
| |
| |
|
| | |
Sales and marketing | |
| 37,977 | |
| 27,431 | |
| 10,546 |
| 38 | % | | |
| 35,602 | |
| 37,977 | |
| (2,375) |
| (6) | % | |
General and administrative | |
| 19,125 | |
| 19,220 | |
| (95) |
| (0) | % | | |
| 19,151 | |
| 19,125 | |
| 26 |
| 0 | % | |
Research and development | |
| 6,197 | |
| 6,179 | |
| 18 |
| 0 | % | | |
| 7,308 | |
| 6,197 | |
| 1,111 |
| 18 | % | |
Total operating expenses | |
| 63,299 | |
| 52,830 | |
| 10,469 |
| 20 | % | | |
| 62,061 | |
| 63,299 | |
| (1,238) |
| (2) | % | |
Loss from Operations | |
| (27,384) | |
| (20,655) | |
| (6,729) |
| (33) | % | | |
| (26,127) | |
| (27,384) | |
| 1,257 |
| 5 | % | |
Other (income) expense: | |
|
| |
|
| |
| |
|
| | | |
|
| |
|
| |
| |
|
| | |
Interest expense | |
| 3,039 | |
| 2,955 | |
| 84 |
| 3 | % | | |
| 3,580 | |
| 3,039 | |
| 541 |
| 18 | % | |
Other income, net | |
| (1,554) | |
| (53) | |
| (1,501) |
| (2,832) | % | | |
| (4,895) | |
| (1,554) | |
| (3,341) |
| (215) | % | |
Net Loss | | $ | (28,869) | | $ | (23,557) | | $ | (5,312) |
| (23) | % | | | $ | (24,812) | | $ | (28,869) | | $ | 4,057 |
| 14 | % | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Revenues by Geography |
| | | Revenues by Geography |
| | ||||||||||||||||
| | Nine Months Ended September 30, |
| | | Nine Months Ended September 30, |
| | ||||||||||||||||
| | 2022 | | 2021 |
| | | 2023 | | 2022 |
| | ||||||||||||
| | | | | % of | | | | | % of |
| | | | | | % of | | | | | % of |
| |
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| |
| Amount |
| Revenues |
| Amount |
| Revenues |
| | ||||
| | (in thousands, except percentages) |
| | | (in thousands, except percentages) |
| | ||||||||||||||||
United States | | $ | 45,893 | | 98 | % | $ | 38,891 | | 97 | % | | | $ | 49,464 | | 97 | % | $ | 45,893 | | 98 | % | |
International | |
| 1,115 |
| 2 | % |
| 1,399 |
| 3 | % | | |
| 1,570 |
| 3 | % |
| 1,115 |
| 2 | % | |
Total revenues | | $ | 47,008 |
| 100 | % | $ | 40,290 |
| 100 | % | | | $ | 51,034 |
| 100 | % | $ | 47,008 |
| 100 | % | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | U.S. Revenues by Product Category |
| | | U.S. Revenues by Product Category |
| | ||||||||||||||||
| | Nine Months Ended September 30, |
| | | Nine Months Ended September 30, |
| | ||||||||||||||||
| | 2022 | | 2021 |
| | | 2023 | | 2022 |
| | ||||||||||||
| | | | | % of | | | | | % of |
| | | | | | % of | | | | | % of |
| |
|
| Amount |
| Revenues |
| Amount |
| Revenues |
| |
| Amount |
| Revenues |
| Amount |
| Revenues |
| | ||||
| | (in thousands, except percentages) |
| | | (in thousands, except percentages) |
| | ||||||||||||||||
NeuroStar Advanced Therapy System | | $ | 11,959 | | 26 | % | $ | 6,945 | | 18 | % | | | $ | 11,936 | | 24 | % | $ | 11,959 | | 26 | % | |
Treatment sessions | |
| 32,627 |
| 71 | % |
| 30,688 |
| 79 | % | | |
| 36,018 |
| 73 | % |
| 32,627 |
| 71 | % | |
Other | |
| 1,307 |
| 3 | % |
| 1,258 |
| 3 | % | | |
| 1,510 |
| 3 | % |
| 1,307 |
| 3 | % | |
Total U.S. revenues | | $ | 45,893 |
| 100 | % | $ | 38,891 |
| 100 | % | | | $ | 49,464 |
| 100 | % | $ | 45,893 |
| 100 | % | |
3128
Revenues
Total revenue for the nine months ended September 30, 20222023 was $47.0$51.0 million, an increase of 17%9% compared to the nine months ended September 30, 20212022 revenue of $40.3$47.0 million. During the nine months ended September 30, 2022,2023, total U.S. revenue increased by 18%8% and international revenue decreasedincreased by 20% over the nine months ended September 30, 2021.41%. The U.S. revenue growth was primarily driven by an increase in Treatment Sessiontreatment sessions sales and the declineincrease in international revenue was primarily driven by a decreasean increase in international NeuroStar Advanced Therapy SystemsSystem and treatment session sales.
U.S. NeuroStar Advanced Therapy System revenue for the nine months ended September 30, 20222023 was $12.0$11.9 million, an increasea decrease of 72%$0.1 million compared to the nine months ended September 30, 20212022 revenue of $6.9$12.0 million. For the nine months ended September 30, 20222023 and 2021,2022, the Company sold 153146 and 92155 systems, respectively, that were recognized as NeuroStar Advanced Therapy System capital revenue during each period. Additionally, for the nine months ended September 30, 2022 and 2021, the Company executed 2 and 7 operating lease agreements respectively, thatwhich contributed to operating lease revenue.
U.S. treatment session revenue for the nine months ended September 30, 20222023 was $32.6$36.0 million, an increase of 6%10% compared to the nine months ended September 30, 20212022 revenue of $30.7$32.6 million. The revenue growth was primarily driven by an increase in the number of accounts utilizing our PHQ 10 tool. As a result, our treatment session volume in our local per click accounts, those utilizing our PHQ 10 tool increased 36.3% compared to prior yearand utilization over comparative period.
Cost of Revenues and Gross Margin
Cost of revenues increased by $3.0$4.0 million, or 37%36%, from $8.1 million for the nine months ended September 30, 2021 to $11.1 million for the nine months ended September 30, 2022. The increase was due2022 to revenue growth versus the prior year period. Gross margin decreased from 79.9%$15.1 million for the nine months ended September 30, 20212023. This increase was primarily due to the recording of a $1.9 million inventory impairment for specialized component parts secured for discontinued NeuroStar Advanced Therapy Systems for which costs exceed net realizable value. Additionally capitalized software and the corresponding amortization expense increased by $1.0 million associated with the latest product release. Finally increases in volume and price related to our Senstars used by our international customers contributed $0.4 million.
Gross margin decreased from 76.4% for the nine months ended September 30, 2022.2022 to 70.4% for the nine months ended September 30, 2023. The decrease in gross margin was primarilydriven by the higher operational costs related to our transition to a resultnew third-party contract manufacturing partner and software amortization expense from the latest product release, the recording of a change in the product mix of revenues versus the prior year period.an inventory reserve and increased Senstar costs.
Sales and Marketing Expenses
Sales and marketing expenses increaseddecreased by $10.6$2.4 million, or 38%6%, from $27.4 million for the nine months ended September 30, 2021 to $38.0 million for the nine months ended September 30, 2022.2022 to $35.6 million for the nine months ended September 30, 2023. The increasedecrease was expected and primarily due to reduced spending in marketing on brand development, as: (a) the new marketingbrand development initiative related costs, including trade shows, digital paid media costscompleted in 2022 and market research, and(b) Neuronetics offered a retention program to sales personnel expenses related to salary, benefits, commissionsin 2022 and share-based compensation incurred versusdid not continue the prior year period.program in 2023, resulting in a decrease in sales personnel expense.
General and Administrative Expenses
General and administrative expenses remained materially consistent from $19.1 million for the nine months ended September 30, 2022 to $19.2 million for the nine months ended September 30, 2021 to $19.1 million for the nine months ended September 30, 2022.2023.
Research and Development Expenses
Research and development expenses remained materially consistent atincreased by $1.1 million from $6.2 million for the nine months ended September 30, 2022 and 2021.
Interest Expense
Interest expense remained constant at $3.0to $7.3 million for the nine months ended September 30, 20212023. The increase was primarily due to higher clinical research and 2022.personnel expenses as the Company continues to look to increase the usability of the NeuroStar Advanced Therapy System.
3229
Interest Expense
Interest expense increased by $0.6 million from $3.0 million for the nine months ended September 30, 2022 to $3.6 million for the nine months ended September 30, 2023 due to an increase in interest rates and debt balance.
Other Income, Net
Other income, net increased by $1.5$3.3 million from $0.05 million for the nine months ended September 30, 2021 to $1.6 million for the nine months ended September 30, 2022 to $4.9 million for the nine months ended September 30, 2023, primarily as a result of the ERC of $2.9 million and increased interest income earned on the Company’s note receivables.money market accounts which was partially offset by an increase in notes receivable interest.
Liquidity and Capital Resources
Overview
On February 2, 2021, we closed on our secondary public offering and sale (the “Offering”) of our common stock in which we issued and sold 5,566,000 shares of our common stock, which included shares pursuant to an option granted to underwriters to purchase additional shares, at a public offering price of $15.50 per share. We received net proceeds of $80.6 million after deducting underwriting discounts, commissions and offering expenses. Our common stock is listed on the Nasdaq Global Market under the trading symbol “STIM”.
As of September 30, 2022,2023, we had cash and cash equivalents of $73.7$35.8 million and an accumulated deficit of $337.6$370.7 million, compared to cash and cash equivalents of $94.1$70.4 million and an accumulated deficit of $308.7$345.9 million as of December 31, 2021.2022. We incurred negative cash flows from operating activities of $27.6$34.2 million and $23.5$27.6 million for the nine months ended September 30, 20222023 and 2021,2022, respectively. We have incurred operating losses since our inception, and we anticipate that our operating losses will continuelessen in the near term as we seek to expandadjust our sales and marketing initiatives, to support our growth in existing and new markets, invest funds in additional research and development activities and utilize cash for other corporate purposes.initiatives. The Company’s primary sources of capital to date have been proceeds from its IPO, the Offering, private placements of its convertible preferred securities, borrowings under its credit facility, proceeds for its secondary public offering of common stock and revenues from sales of its products. As of September 30, 2022,2023, the Company had $35.0$37.5 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025.March 2028. Subsequent to September 30, 2023, the Company drew down an additional $22.5 million pursuant to the terms of its amended credit facility. Management believes that the Company’s cash and cash equivalents as of September 30, 20222023 and anticipated revenues from sales of its products are sufficient to fund the Company’s operations for at least 12 months from the issuance of these financial statements.
If our cash and cash equivalents and anticipated revenues from sales orof our products are insufficient to satisfy our liquidity requirements, we may seek to sell additional common or preferred equity or debt securities or enter into a new credit facility or another form of third-party funding or seek other debt financing. If we raise additional funds by issuing equity or equity-linked securities, our stockholders would experience dilution and any new equity securities could have rights, preferences and privileges superior to those of holders of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all. It is also possible that we may allocate significant amounts of capital towards products or technologies for which market demand is lower than expected and, as a result, abandon such efforts. If we are unable to maintain our current financing or obtain adequate additional financing when we require it, or if we obtain financing on terms whichthat are not favorable to us, or if we expend capital on products or technologies that are unsuccessful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, or we may be required to delay the development, commercialization and marketing of our products.
Our current and future funding requirements will depend on many factors, including:
● |
our ability to achieve revenue growth and improve operating |
● | compliance with the terms and conditions, including covenants, set forth in our credit facility; |
33
● | the cost of expanding our operations and offerings, including our sales and marketing efforts; |
30
● | our ability to improve or maintain coverage and reimbursement arrangements with domestic and international third-party and government |
● | our rate of progress in establishing coverage and reimbursement arrangements from international commercial third-party and government payors, particularly in Japan; |
● | our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of our products and maintaining or improving our sales to our current customers; |
● | the cost of research and development activities, including research and development relating to additional indications of neurohealth disorders; |
● | the effect of competing technological and market developments; |
● | costs related to international expansion; and |
● | the |
As of September 30, 2022,2023, there were no significant changes to our material cash requirements as set forth in our Form 10-K, filed with the SEC on March 8, 2022.7, 2023.
Cash Flows
The following table sets forth a summary of our cash flows for the nine months ended September 30, 20222023 and 2021:2022:
| | | | | | | | | | | | | |
| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | ||||||||
|
| 2022 |
| 2021 | |
| 2023 |
| 2022 | ||||
| | (in thousands) | | | (in thousands) | ||||||||
Net Cash Used in Operating Activities | | $ | (27,639) | | $ | (23,459) | | | $ | (34,171) | | $ | (27,639) |
Net Cash Provided by (Used in) Investing Activities | |
| 7,234 | |
| (9,038) | | ||||||
Net Cash (Used in) Provided by Financing Activities | |
| (38) | |
| 82,974 | | ||||||
Net (Decrease) Increase in Cash and Cash Equivalents | | $ | (20,443) | | $ | 50,477 | | ||||||
Net Cash (Used in) Provided by Investing Activities | |
| (759) | |
| 7,234 | |||||||
Net Cash Provided by (Used in) Financing Activities | |
| 437 | |
| (38) | |||||||
Net (Decrease) in Cash and Cash Equivalents | | $ | (34,493) | | $ | (20,443) |
Net Cash Used in Operating Activities
Net cash used in operating activities for the nine months ended September 30, 2023 was $34.2 million, consisting primarily of a net loss of $24.8 million and an increase in net operating assets of $19.3 million, partially offset by non-cash charges of $9.9 million. The increase in net operating assets was primarily due to an increase in accounts receivable, the ERC and a decrease in accrued expenses. Non-cash charges consisted of depreciation and amortization, inventory impairment, non-cash interest expense, and share-based compensation.
Net cash used in operating activities for the nine months ended September 30, 2022 was $27.6 million, consisting primarily of a net loss of $28.9 million and an increase in net operating assets of $7.1 million, partially offset by non-cash charges of $8.3 million. The increase in net operating assets was primarily due to increases in accounts receivable and inventory and decreases in accounts payable as a result of timing. Non-cash charges consistedtiming of depreciation and amortization, non-cash interest expense, share-based compensation, and the cost of rental units purchased by customers.
Net cash used in operating activities for the nine months ended September 30, 2021 was $23.5 million, consisting primarily of a net loss of $23.6 million and an increase in net operating assets of $7.5 million, partially offset by non-cash charges of $7.6 million. The increase in net operating assets was primarily due to increases in accounts receivable and inventory and decreases in accounts payable and accrued expenses as a result of timing and the 2021 payment of the 2020 bonus compensation accrued as of December 31, 2020.payments. Non-cash charges consisted of depreciation and amortization, non-cash interest expense, share-based compensation, and the cost of rental units purchased by customers.
3431
Net Cash (Used in) Provided by and Used in Investing Activities
Net cash used in investing activities for the nine months ended September 30, 2023 was $0.8 million, which was attributable to purchases of property and equipment and capitalized software costs partially offset by the repayment of our notes receivable.
Net cash provided by investing activities for the nine months ended September 30, 2022 was $7.2 million which was attributable to the repayment of our promissory note which were partially offset by purchases of property and equipment and capitalized software costs.
Net used in investing activities for the nine months ended September 30, 2021 was $9.0 million which was due to the issuance of our promissory note and purchases of property and equipment and capitalized software costs.
Net Cash Provided by (Used in) Financing Activities
Net Cash Usedcash provided by financing activities for the nine months ended September 30, 2023 was $0.4 million and primarily consisted of the additional debt net of the final payment and amendment fee paid in and Provided by Financing Activitiesconnection with the Solar Fourth Amendment.
Net cash used in financing activities for the nine months ended September 30, 2022 was $0.04 million and consisted of the amendment fee paid in relation to a 2022 amendment to the 2022 Solar Amendment,Facility, which was offset by cash proceeds related to stock option exercises.
Net cash provided by financing activities for the nine months ended September 30, 2021 was $82.9 million and primarily consisted of additional proceeds from our Offering and cash proceeds related to stock option exercises.
Indebtedness
Refer to “Note 13. Debt”“Debt” in our unaudited financial statements and related notes thereto appearing elsewhereNotes to Interim Financial Statements located in this Quarterly Report on Form 10-Q for information regarding our current Solar credit facility.
Common Stock Offering
Refer to “Note 14. Common Stock” in our unaudited financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-QPart I – FINANCIAL INFORMATION, Item 1. Financial Statements for information regarding the Offering.Solar Facility.
JOBS Act Accounting Election
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act,(the “JOBS Act”), and are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, or Securities Act, for complying with new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable.
Recent Accounting Pronouncements
We refer youRefer to “Note 3. Summary“Summary of Significant Accounting Policies” and “Note 4. Recent“Recent Accounting Pronouncements” in “NotesNotes to Interim Financial Statements”Statements located in “PartPart I – FINANCIAL INFORMATION, Item 1. Financial Statements.”
35
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We refer youRefer to the information described in the “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” section ofin the Company’s Annual Report on Form 10-K filed with the SEC on March 8, 2022.7, 2023. There have been no material changes to our market risk described therein.
We continue to monitor inflationary factors, such as increases in our cost of revenues and operating expenses that may adversely affect our operating results. Although we have begun to experience price increases in certain parts of our business,do not believe inflation for the nine months ended September 30, 2022 has not had a significantmaterial impact on our financial condition, results of operations or cash flows to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin or decrease
32
our operating expenses as a percentage of our revenues if ourthe selling prices of our products do not increase as much or more than our costs increase.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Principal Executive Officer and ChiefPrincipal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Principal Executive Officer and our ChiefPrincipal Financial and Accounting Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2022.2023.
Changes in Internal Control over Financial Reporting
During the quarter ended September 30, 2022,2023, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) whichthat materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
3633
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
We are subject from time to time to various claims and legal actions arising during the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations, financial condition, or cash flows.
Item 1A. Risk Factors.
You should carefully consider the information described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the SEC on March 8, 2022.7, 2023. There have been no material changes to the risk factors described therein.
Item 2. Unregistered Sales of Equity Securities, and Use of Proceeds.Proceeds and Issuer Purchases of Equity Securities.
Not applicable.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Not applicable.Rule 10b5-1 Trading Plans
On August 28, 2023, W. Andrew Macan, the Company’s Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 34,991 shares of the Company’s common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is until the earlier of December 29, 2023, or the execution of all trades as contemplated by the trading arrangement.
During the three months ended September 30, 2023, no other director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Chief Executive Officer Severance-Related Modifications
On November 2, 2023, the Company’s board of directors directed the Company to: (A) amend its employment agreement with Keith J. Sullivan, the Company’s President and Chief Executive Officer, to: (i) extend, from 18 months to 24 months, the duration of Mr. Sullivan’s severance benefits if the Company terminates Mr. Sullivan’s employment without cause, or if Mr. Sullivan resigns for good reason, within 12 months of a change in control; and (ii) reflect Mr. Sullivan’s current annual base salary, as approved by the Company’s board of directors via unanimous written consent on February 8, 2023, in lieu of the outdated annual base salary as reflected in such employment agreement prior to such amendment; and (B) take any other actions necessary to effectuate such amendments, which may include an amendment to any ancillary agreements by and between Mr. Sullivan and the Company regarding any such severance benefits. The Company expects to execute all such amendments during the quarter ending December 31, 2023.
34
Item 6. Exhibits.
The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q. Where so indicated, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated.
| | | |||
Exhibit |
| Description | |||
| | | |||
10.1◊ | | ||||
31.1* | | ||||
31.2* | | ||||
32.1** | | ||||
32.2** | | ||||
| |
| |||
101.SCH | | Inline XBRL Taxonomy Extension Schema Document | |||
101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||
101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||
101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document | |||
101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||
104 | | Cover Page Interactive Data File (Formatted as Inline XBRL and |
* | Filed herewith. |
37
◊ | Certain portions of this exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC or its staff upon request. |
** | This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C Section 1350 and is not being filed for purposes of Section 18 of the |
3835
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act, of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
|
| NEURONETICS, INC. | |
| | (Registrant) | |
Date: November | | By: | /s/ Keith J. Sullivan |
| | Name: | Keith J. Sullivan |
| | Title: | President and Chief Executive Officer |
| | | (Principal Executive Officer) |
Date: November | | By: | /s/ Stephen Furlong |
| | Name: | Stephen Furlong |
| | Title: |
|
| | | (Principal Financial and Accounting Officer) |
3936